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Estrogen is a driver for the development and progression of luminal breast cancer, and 
up to 80% of all breast cancers diagnosed belong to the luminal subtype. The 
estrogenic effect on breast tumors can be reduced by the adjuvant use of the anti-
estrogenic drug tamoxifen, which has significantly improved outcomes in luminal 
breast cancer patients over the last several decades. The 10-year recurrence rate in 
luminal breast cancer patients is approximately 25%. Thus, some patients do not 
achieve the desired curative effect of adjuvant tamoxifen. Tamoxifen is regarded as a 
weak anti-estrogen, and the anti-estrogenic effect is believed to be dependent on its 
active metabolites endoxifen and 4OHtam, which have up to 100-fold higher affinities 
to the estrogen receptor (ER) compared to tamoxifen itself. Worryingly, a significant 
subgroup of patients has a reduced ability to metabolize the drug, which translates into 
lower concentrations of the important active metabolites. Studies have indicated that 
these patients derive suboptimal therapeutic effects from tamoxifen. In addition, a 
large number of patients using tamoxifen discontinue treatment before the pre-
determined treatment time, which may leave these patients at higher risk of relapse.  
Therefore, increasing knowledge about the function of and determining possible 
therapeutic thresholds for the active metabolites represent promising potential progress 
towards individualized tamoxifen treatment and thereby improve patient outcomes. 
Identifying biomarkers that predict tamoxifen discontinuation may also be used to 
further tailor individual treatment.  
In paper I, we performed microarray global gene expression analyses on NDtam, 
4OHtam and endoxifen-treated MCF-7 cells to elucidate the gene regulative roles of 
these metabolites. Global gene expression analyses revealed a step-wise regulation of 
genes in which endoxifen and 4OHtam resulted in the strongest and second strongest 
regulation of both up- and down-regulated genes, respectively. The change in global 
gene expression after treatment with NDtam was minimal. The two active metabolites 
regulated genes in similar gene ontology classes, implying a degree of similar function 





CytoKeratin6 (CK6) being estrogen regulated, making CK6 a potential anti-
proliferative target of tamoxifen that should be researched further. 
In paper II, we retrospectively compared the predictive value of CYP2D6 phenotype 
groups and concentrations of active tamoxifen metabolite on long-term clinical 
outcome. Blood and serum from 99 operable breast cancer patients treated with 5-year 
adjuvant tamoxifen were analyzed for CYP2D6 genotypes and concentration levels of 
active tamoxifen metabolites, respectively. CYP2D6 phenotypes were found to be 
correlated to Z-endoxifen and Z-4OHtam concentrations. However, Kaplan-Meier 
analyses showed that CYP2D6 phenotypes were not associated with breast cancer 
specific-survival (BCSS). The same analyses were repeated using concentrations of 
tamoxifen metabolites; patients with concentrations below 9 nM and 3.26 nM for Z-
endoxifen and Z-4OHtam, respectively, had significantly worse BCSSs compared to 
patients with concentrations above these cut-off points. When we included a third cut-
off point, representing patients with high concentration levels found in CYP2D6 ultra-
rapid metabolizers, we found that these patients had no BCSS endpoints up to 19 years 
after surgery. The BCSS results from these three groups also translated into overall 
survival. Our findings indicate that the concentrations of active tamoxifen metabolites 
may be used to predict the therapeutic effects of tamoxifen.  
In paper III, we investigated the association between tamoxifen metabolites and side 
effects in 220 patients that delivered blood samples and patient reported outcome 
measures yearly from 2011 to 2017. Analyses of side effects revealed hot flashes, 
vaginal atrophy symptoms, and joint pain to be most prevalent. Association analyses 
demonstrated that patients with high levels of tamoxifen, Z-4’OHtam and tamNoX 
were more likely to report vaginal dryness than patients with lower levels. Our 
secondary objective was to compare discontinuation rates obtained through the 
Norwegian prescription database to rates determined by longitudinal drug monitoring 
of systemic tamoxifen concentrations. Drug monitoring showed that only 6% of 
patients were not taking tamoxifen during a period that was covered by a tamoxifen 
prescription. Our results indicate that drug monitoring of tamoxifen metabolites may 
be used as biological predictor of vaginal dryness and that discontinuation rates 
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1.1 Tumorigenesis and the hallmarks of cancer 
Cancer is a vastly diverse and heterogeneous disease with over 100 different types 
arising from a range of tissues and cell types within the body. The various cancer types 
grow and behave differently, and cancer is therefore often referred to as a “collection 
of diseases.” Yet, there are common traits that are shared by all cancers, described by 
Douglas Hanahan and Robert A. Weinberg as the hallmarks of cancer (Fig. 1) (1, 2).  
 







HALLMARKS OF CANCER 
Genome instability and mutations, changes in genes are caused by accumulation of mutations through 
enhanced sensitivity to mutagenic agents and/or attenuating mutations of genes involved in controlling growth 
and proliferation.  
Tumor promoting inflammation, release of growth factors and mutagenic chemicals into the tumor 
microenvironment by immune cells can fuel mutagenesis and proliferation of the cancer cells.  
Ability to sustain proliferative signaling, cancer cells can become self-sufficient in growth factors by 
abnormal autocrine growth factor signaling and/or acquire increased sensitivity to growth factor stimulus. 
Cancer cells may also stimulate normal cells to produce growth factors and/or become independent of growth 
factors by consecutive activation of downstream signaling pathways.  
Ability to evade growth suppressors, cancer cells exhibit inactivating mutations in tumor suppressors that 
halt the progression of the cell cycle in response to growth inhibitory signals, DNA damage, stress and other 
abnormalities.  
Ability to resist apoptosis, cancer cells survive through loss of tumor suppressors, down-regulation of pro-
apoptotic factors, up-regulation of anti-apoptotic and survival signals, and/or disruption of extrinsic ligand-
induced apoptosis pathways.  
Ability for unlimited replication potential, up-regulation of telomerase, a DNA polymerase that adds 
telomere repeats to the telomeric DNA, allows cancer cells to continue dividing without shortening of 
telomeres. Also, in the absence of p53 some cancer cells may continue dividing with eroded telomeres and 
commence chromosomal breakage-fusion-bridge cycles resulting in massive chromosomal alterations.   
Inducing angiogenesis, a normally strictly regulated process can be constantly “turned on” in cancer by 
deregulation of signaling proteins including vascular endothelial growth factor-A (VEGF-A) and 
thrombospondin-1 (TSP-1) thereby providing a constant flow of nutrients and draining of waste products to and 
from the tumor.  
Activating invasion and metastasis, a multi-step process that frequently starts with the loss of cell-to-cell or 
cell-to-matrix adhesion molecules such as E-cadherin allows for local invasion. Further steps include the 
intravasation of cancer cells into blood or lymph vessels facilitating transport to distant sites where the cells can 
escape the vessels through extravasation and form micro metastases. An important facilitator of this process is 
the epithelial to mesenchymal transition (EMT) facilitated by the expression of developmental transcription 
factors like the Snail, Slug and Twist. The last step is colonization in which the micro metastases grow into 
new tumors distant from the primary tumor.  
Ability to reprogram energy metabolism, surprisingly, most cancer cells apply the cytoplasmic glycolysis 
instead of mitochondrial oxidative phosphorylation, a far less efficient method of producing energy (2 vs. 38 
ATP). It is believed that glycolysis allows for improved generation of nucleosides and amino acids, important 
components when producing new cells. Certain areas of the tumor may also be hypoxic, requiring anaerobic 
energy production through glycolysis.  
Ability to evade destruction by immune cells, normally, the immune system will destroy incipient cancer 
cells, however natural selection towards weakly immunogenic cancer cells over time is believed to create 
cancer cells that avoid detection by immune cells. Other mechanisms for avoiding immune detection include 
secretion of immunosuppressive factors and recruitment of immune cells that suppress the action of cytotoxic 
lymphocytes.  
Table 1. Hallmarks of cancer. The first two hallmarks are enabling characteristics. 





1.2 Breast cancer 
 Breast anatomy 1.2.1
The female breast is an exocrine modified apocrine sweat gland overlying the pectoral 
muscles, predominantly consisting of glandular and duct epithelium and adipose and 
connective tissues (Fig. 2A). From the formation of the epidermal breast bud, 
commencing in the 7th gestational week (3), to old age, the breast is constantly 
undergoing changes due to ever-changing estrogen and progesterone levels throughout 
life (4). Under the influence of increased estrogen and progesterone production in 
puberty, the stem cells in the terminal ductal lobular unit (TDLU) of the breast bud 
(Fig. 2B and C) initiate sprouting and growth of parenchymal breast tissue into the 
adjacent connective and adipose tissues (3). There are two major types of stem cells in 
the TDLU: luminal stem cells and basal stem cells. Luminal stem cells are orientated 
towards the lumen of the apocrine glandular alveoli and the lumen of the terminal 
ducts of the breast. These are cells that predominantly express ERs and progesterone 
receptors (PRs), or ER+/PR+ cells. Basal stem cells are located between the luminal 
cells and the basement membrane (Fig. 2C). These stem cells are ER-/PR- and are also 
the origin of the myoepithelial cells, which comprise smooth muscular fibers that can 
contract and squeeze excreted milk from the alveoli through a network of lobules, 
lobes and ducts to the nipple. The lobes and ducts are surrounded by fibroblasts, 
macrophages, and adipose tissue that make up the microenvironment of the TDLU. 
The ratio between connective, adipose, and glandular tissues shows substantial 
individual variation. In addition, this ratio is highly influenced by age. In the 
postmenopausal breast, an involution of glandular tissue and incremental increase of 
adipose tissue occur. A high ratio of glandular and connective tissue compared to 
adipose tissue is described as high breast density, a condition associated with increased 
risk of developing breast cancer (5). Lymphatic vessels of the breast drain to two 
major lymph node locations: the intra-pectoral and the axillar locations. The latter 
route is the most accessible during surgery, and in a normal breast, the average number 





the first recipient lymph node is known as the sentinel node–is an important prognostic 
marker in breast cancer and is used in the staging of the disease (6).  
 
Figure 2. Breast anatomy. A) Gross anatomy of the breast. Artwork by Patrick J. 
Lynch, medical illustrator. B) Illustration of branching of the ductal system down into 
the TDLU. Modified from (7). C) Overview of various stem cells, luminal and basal 
cells in the TDLU and the various cells in the microenvironment of the TDLU. ER, 
estrogen receptor; PR, progesterone receptor; TDLU, terminal ductal lobular unit. 
Modified from (8). 
 Breast cancer epidemiology 1.2.2
Breast cancer is the most frequent form of cancer for women throughout the world, 
with over 1.6 million incidences registered in the latest update from 2012 (9). In the 
same year, over half a million breast cancer deaths were registered, making breast 





the world-wide cancer burden for 2018 suggest over 2 million new incidences and 
600 000 deaths from breast cancer (10). Breast cancer is also the most frequent form 
of cancer among Norwegian women, with 3371 new incidences in 2016. 
Approximately 1 in 12 women in Norway will develop breast cancer by the age of 75, 
and the median age of developing the disease is 62 (11). In Norway, breast cancer 
ranks third in mortality, behind lung and colon cancer, with 585 deaths in 2015 (not 
updated for 2016).  
Despite the high number of deaths and increasing incidences, breast cancer mortality 
has been decreasing in the western world over the last several decades (9). The 
improvement in survival is attributed to earlier detection through screening programs 
and improvements in treatment (12). This trend has also been observed in Norway 
where from 1965 to 2015 there was an increase in incidence, but at the same time, an 
increase in the 5-year survival rate and a decrease in mortality (11).  
 Breast cancer etiology and risk factors 1.2.3
The lifetime risk of developing breast cancer for a Norwegian woman is about 10 % 
(11). The etiological and risk factors can be classified into four groups: genetic-, 
hormonal/reproductive-, lifestyle-, and environmental factors. 
  Genetic factors 1.2.3.1
The strongest germline genetic factor is the female X sex chromosome. Being female 
(homozygote XX) is associated with a risk of developing breast cancer 100 times 
greater than being male (XY) (13), and this increased risk is attributed to the higher 
estrogen levels in women compared to men. Besides sex chromosomes, approximately 
5-10% of all breast cancers are caused by germline mutations in somatic 
chromosomes. Founder mutations in breast cancer genes 1 and 2 (BRCA1, 2) on the 
17th and 13th chromosome, respectively, are high-penetrant gene mutations, leaving a 
woman who has a BRCA-1 mutation with a 45-75% lifetime risk of developing breast 
cancer (14). Mutations in TP53, PTEN, STK11 and CDHI have also been associated 





  Endocrine factors 1.2.3.2
Three types of sex-hormones, estrogens, progesterone, and androgens all influence the 
risk of acquiring breast cancer. However, estrogen is the most important factor due to 
its dual carcinogenetic action: mutagenic effects and activation of ERs. The mutagenic 
effect is caused by DNA adducts that are formed when DNA is bound by oxidative 
metabolites of estrogen. These DNA adducts can cause DNA damage through 
depurination of adenine and guanine, oxidative damage, and alkylating reactions, all of 
which can lead to mutations (16). Stem cells in TDLUs are under constant influence of 
estrogens throughout the fertile years and are therefore at risk of accumulating 
mutations created by endogenous estrogens and exogenous mutagen factors. The 
second carcinogenic action of estrogens is mediated through the activation of ERs, 
which leads to alterations in the transcription of over 1000 genes (17). The cellular 
effects translate into increased proliferation, reduced apoptosis, and increased growth 
via activation of PR production (16). 
Reproductive factors that increase the endogenous estrogen influence on stem cells are 
early menarche, late menopause, late 1st pregnancy, lack of breastfeeding and 
nulliparous status (never given birth). Postmenopausal obesity is also associated with 
higher levels of endogenous estrogens as conversion of adrenal androgens to estrogens 
occurs in adipose tissue. An exogenous factor is prolonged hormone replacement 
therapy (estrogens and progestins). Oral contraceptive use is a putative factor, but 
results from various studies are ambiguous (13).  
  Environmental and lifestyle factors 1.2.3.3
Chemical agents with estrogen-like action, such as polychlorinated biphenyls (widely 
used in the past in cooling liquids for electric apparatuses) and pesticides like DDT, 
have been shown to cause mutagenic effects through the formation of DNA adducts 
(18). Similar to estrogen, they are able to bind to ERs and activate transcription. 
Electromagnetic fields (19) and high exposure to ionizing radiation (20) are additional 
environmental factors which have been linked to increased risk of developing breast 
cancer. Lifestyle factors associated with increased breast cancer risk include the usual 





alcohol consumption (18). A high level of physical activity, however, has been shown 
to have a protective effect (22). 
 Breast cancer predictive and prognostic factors 1.2.4
Breast cancer is a heterogeneous disease and can be divided into four clinical subtypes 
based on predictive and prognostic markers (Table 1) (23). Prognostic factors are 
predictive of clinical outcome and prognosis independent of treatment, while 
predictive factors give information on probable patient response to treatment (24). 
Importantly, prognostic factors can only be determined in materials comprising 
treatment naïve patients (25). Nodal status and tumor size are prognostic factors 
determined by histopathological analyses of primary breast cancer samples. One of the 
most important microscopic features with substantial prognostic information is the 
histological grading (HG) system. It consists of an algorithm comprising three cellular 
features; percentage tubular formation (1-3 points), nuclear pleomorphism (1-3 points) 
and mitotic index (1-3 points). These add up to a scale from 3 to 9 points. A higher 
score indicates poorly differentiated cancer. A sum score of 3-5 is categorized as HG 
1, 6-7 points as HG 2, and 8-9 as HG 3, and there are clear prognostic differences 
between these grades, with HG 1 representing the best prognosis and HG 3 the poorest 
prognosis. Interestingly, gene profiling of these three histological grades reveals that 
there are only two genuine genetic grading (GG) groups; genetic grade 1 and genetic 
grade 2. All HG1 cancers cluster in the GG1 group and all HG3 cluster in the GG2 
group, while HG2 cancers are a mixture of both GG1 and GG2 cancers (26).  
Predictive factors include expression levels of ER, PR, and the human epidermal 
growth factor-2 (EGFR2) also known as the human EGF receptor-2/neu (HER-2/neu). 
ER and PR status is assessed by immunohistochemistry (IHC) and HER2 status is 
determined by fluorescence in situ hybridization. These growth stimulatory receptors 
can be directly or indirectly targeted by drugs and their expression levels are predictive 
of response to these treatments. However, outcome studies of untreated patients show 
that these predictive factors are also prognostic, as HER-2 positive patients have 
poorer outcomes compared to HER-2 negative patients, and patients with high 





(27). An additional factor that has mixed prognostic and predictive significance is the 
cell cycle protein Ki67. High Ki67 protein levels in cancer cells indicate high 
proliferation and poorer prognoses. But high Ki67 may also be predictive of better 
response to chemotherapy. However, Ki67 is somewhat controversial as its IHC 
measuring method has not been adequately standardized resulting in variations 
between laboratories, and no consensus on cut-off values has been established (28, 
29). All these prognostic and predictive factors are routinely measured in the clinical 
setting, and their combinations are used to guide clinicians in their decisions on 
treatment for breast cancer patients (Table 1) (23, 24). In breast cancer, there exist 
over 100 prognostic factors, but few predictive factors. There is thus a need to 





Triple negative (ER-, PR-, 
HER2-) 
ER-, PR-, HER2- CT 




HER2-, HR+, high ER/PR and low Ki-
67 or low grade  
ET, (CT if stage>2)  
Luminal B-like 
HER2-, HR+, lower ER/PR, high Ki-
67, grade 3 
ET, (CT)  
Table 2. The four main subtypes used in the clinical setting. ER, estrogen receptor; 
PR, progesterone receptor; HER2, human epidermal growth factor-2; HR, hormone 
receptor; CT, chemotherapy (either taxanes or Epirubicin and Cyclophosphamide); 
ET, endocrine treatment. Adapted from (23). 
 Molecular subtyping of breast cancer 1.2.5
The heterogeneity of breast cancer cannot be fully captured by the clinicopathological 
markers discussed above. In the early 2000s two microarray studies using gene sets 
that reflect the intrinsic properties of breast cancer tumors showed that breast cancer 
can be classified into molecular subtypes based on unsupervised hierarchal cluster 





showed that ER-negative and positive tumors are inherently distinct on a molecular 
level and comprise subgroups that are separated based on expression of genes 
associated with specific cell types (Fig. 3). In their pivotal study, Sørlie and Perou 
demonstrated that the ER-negative tumors express genes associated with basal cells 
and adipose cells, while ER-positive tumors (discussed in more detail in sections 
below) express genes associated with luminal cells. The subtypes were also shown to 
be prognostically distinct in which the luminal subtypes exhibit the best prognosis and 
the basal subtype the worst after 5 years of follow-up (31) (Fig. 4A). However, a 
Norwegian study with 20 years follow-up using surrogate biomarkers to determine 
subtypes showed that the luminal subtypes are subject to late breast cancer events 
which leads to similar survival rates to the basal subtype at 20 years (27) (Fig. 4B). 
More recently, two additional subtypes have been suggested: the claudin-low (32) and 
the molecular apocrine (33) subtypes. Molecular portraits of tumors laid the 
foundation for the commercial gene signature assays, such as the Mammaprint, 
Oncotype Dx, and PAM50 (34-36), that are now used to clinically identify low-risk 






Figure 3. Molecular subtypes of breast cancer. Prognosis based on short-term 
follow-up (~5-years). TF=transcription factor, ER=estrogen receptor, 








Figure 4. A. Short-term relapse-free survival analysis comparing the six molecular 
subtypes described in an unsupervised gene expression analysis (31). B. Long-term 
breast cancer specific survival among molecular breast cancer subtypes (27). Notably, 
the survival curves of the luminal subtypes have a negative slope of all the way down 
to 20-years follow-up. Thus, they have a good short-term survival (5 years), but a 
considerable worse long-term survival (20 years). HER2, human epidermal growth 
factor-2. 
1.3 The luminal subtype of breast cancer 
 Molecular characteristics of luminal breast cancer 1.3.1
The luminal subtype of breast cancer is characterized by expression of a cluster of 
transcription factors including the following: the estrogen receptor α (ESR1), X-box 
binding protein 1 (XBP1), GATA-binding protein 3 (GATA3), hepatocyte nuclear 
factor 3α (HNF-3α), and increased expression of genes normally expressed in breast 
luminal epithelial cells (30). The luminal subtype is further divided into luminal A and 
luminal B based on the level of expression of the above-mentioned transcription 
factors. Luminal A tumors presents with higher expression of these genes compared to 
luminal B tumors. The luminal B subtype is further differentiated from luminal A by 
higher expression of proliferation-related genes such as MKI67, CCNB1 and MYBL2 





(39). In addition, luminal B cancer may or may not be HER2 positive while luminal A 
is always HER2 negative. In one study, a third subgroup, luminal C, was distinguished 
from A and B by its expression of a novel gene set with unknown function, which was 
also observed in ER-negative subtypes, but this could not be reproduced in later 
studies (39). Importantly, the luminal breast cancer subtypes comprise a special 
intrinsic biology, which extends into a characteristic survival pattern that comprise 
breast cancer related events during the whole course of the disease (27) (Fig. 4). 
 Nuclear receptors 1.3.2
Clinically, the most important characteristic of luminal subtypes is the expression of 
ER, a member of the nuclear hormone receptor (NR) family. This family of 48 
evolutionarily related, ligand inducible transcription factors (40) regulates genes 
involved in development, reproduction, homeostasis, and differentiation (41). 
Structurally and functionally conserved domains of nuclear receptors include the 
DNA-binding domain (DBD) and the ligand-binding domain (LBD) (Fig. 5). The 
latter also incorporates domains responsible for nuclear localization, dimerization, and 
activating function (AF)-2. A ligand-independent activating function domain, AF-1, is 
found in the length and sequence variable N-terminal domain. Less conserved hinge 
regions connect the ligand-binding domain and the DNA-binding domains. Generally, 
binding of a ligand to the LBD leads to dimerization to other ligand-bound NRs, 
nuclear localization, and binding of the activated dimer to promotors or enhancers of 
target genes. Binding of a ligand also leads to change in the conformation of the AF-2, 
which allows binding of co-regulators. However, other mechanisms for the activation 












Figure 5. Structural and functional domains in nuclear receptors. The A/B domain 
contains the activating function (AF-1) domain; the C domain contains the DNA-
binding domain and a dimerization domain; the D domain consists of the hinge region; 
the E domain contains the ligand-binding domain; and nuclear receptors may or may 
not contain the F domain, which is of unknown function and a region with variable 
sequences among the NRs. Modified from (44). 
 The estrogen receptor and its transcriptional mechanisms 1.3.3
The ER is a nuclear steroid hormone receptor that exists in two subtypes, ERα and 
ERβ. ERα was first discovered in 1967 by Elwood Jensen (45), and the gene (ESR1) 
encoding the receptor was later described in 1986 (46, 47), while ERβ was first 
described in 1996 (48). In addition, splice variations lead to existence of several 
isoforms of both ERα (n=7) and ERβ (n=5) (49-51).  ERα and ERβ are highly 
conserved in structure in the DBD (97%) and less conserved in the LBD (55%), and 
expression levels of the two subtypes vary among tissue types. Both ER subtypes are 
expressed in luminal cancers and may form homodimers (ERα/ERα, ERβ/ERβ) or 
heterodimers (ERα/ERβ) upon binding of ligands. The role of ERβ in breast cancer 
development and progression is unclear, and its potential clinical value remains to be 
determined (52). ERα is, in contrast, overexpressed in over 70% of breast cancers, and 
luminal breast cancer progression is associated with deregulation of the ERα target 
genes involved in differentiation, proliferation, and migration (53). ERα transcription 
is activated through the classical NR activation pathway or three non-classical 
pathways (Fig. 6). The classical pathway involves the binding of 17β-estradiol (E2) to 
cytoplasmic ERα, followed by a conformational change causing the ERα to dissociate 
from inactivating chaperons. After separating from the chaperons, ERα form dimers 
with other ligand-bound ERs and translocate to the nucleus, binding to cis-regulatory 
elements on DNA called estrogen response elements (EREs). Importantly, the binding 
of E2 to ER induces the rotation of helix-12, which exposes binding sites, allowing for 





recruitment of the transcriptional machinery to instigate transcription. ERα may also 
regulate the transcription of genes that do not have EREs (56, 57). In this non-classical 
pathway, E2-activated ERα bind to transcription factors associated with their target 
promotors and facilitate the transcription of genes that lack ERE. In a second non-
classical pathway, growth factor stimulation and the consequent activation of their 
downstream signaling pathways may activate ERα in a ligand-independent manner 
through phosphorylation of ERα by down-stream kinases (58). The third non-classical 
pathway involves ERα transcriptional regulation in a non-genomic manner. In this 
scenario, membrane-bound ERα can be activated by E2 and activate proteins of other 
signaling pathways, thereby indirectly regulating transcription of the pathway’s 
downstream targets (58). Adding to the complexity, the transcriptional activity of ERs 
can be further regulated by interaction with co-regulators (corepressors and 
coactivators) (59) and post-translational modifications including SUMOylation, 








Figure 6. Activation of ER transcriptional regulation. 1) Classical NR activation 
pathway. 2) ERE-independent pathway. 3) Ligand-independent pathway. 4) Non-
genomic pathway. ICSP, intracellular signaling pathway; TF, transcription factor; ER, 
estrogen receptor; ERE, estrogen response element; E2, 17β-estradiol; GFR, growth 
factor receptor; P, phosphate. 
 
1.4 Endocrine treatment 
 Concept and history of endocrine treatment of breast cancer 1.4.1
The rationale for endocrine treatment of breast cancer is to inhibit the growth 
stimulatory effect of estrogen on tumor cells. This can be achieved through ablation of 
estrogen or by inhibition of the ER. Today, three classes of drugs dominate endocrine 
treatment of luminal breast cancer: aromatase inhibitors (AIs), selective estrogen 
receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) (Fig. 





and their long-term use in the adjuvant setting is one of the main reasons for the 
significant improvement in survival rates for luminal breast cancer patients (61, 62).  
However, the road to that improvement was long. It began in 1896 when George T. 
Beatson discovered that ovarian ablation reduced tumor progression (63). He had 
unknowingly inhibited the growth stimulatory effect of estrogen before estrogen and 
its receptor had been characterized. Subsequently, castration by surgery or radiation 
became a frequent part of the palliation of advanced breast cancer, and the concept of 
estrogen ablation was further introduced to post-menopausal therapies in the 1950s 
through adrenalectomy and hypophysectomy (64). During the same time period, a 
rather counterintuitive concept of endocrine treatment involving administration of 
high-dose synthetic estrogens to patients with advanced diseases was developed (65). 
Tumor regression after high dose estrogens or androgens was demonstrated in several 
clinical trials, and the treatment became standard palliative care from the early 1960s 
(66). However, both synthetic estrogens and surgical estrogen ablation had rather 
negative safety images, and the search for more targeted drugs continued. The first AI, 
aminoglutethimide, was introduced in the 1970s as a “medical adrenalectomy” (67), 
although it was later discovered that the drug actually inhibited the aromatase enzyme 
and not adrenal androgen synthesis (68). Less toxic second-generation AIs soon 
followed. The first SERM, tamoxifen was also developed during the late 1960s. This 
antiestrogen drug showed less toxicity than high-dose synthetic estrogen in clinical 
trials and soon became the preferred palliative drug. However, the real revolution in 
endocrine treatment came when the long-term anti-tumor effects of tamoxifen were 
demonstrated, which subsequently led to its use in long-term adjuvant treatment (69), 
a concept later transferred to third generation AIs (70). The first SERD was introduced 
in the early 1990s after further development of a steroidal compound first known as 
ICI 164,384. This pure antiestrogen, named fulvestrant, displayed a unique mechanism 
of ER inhibition that could inhibit growth in tamoxifen-resistant tumors (71). It later 
became an important drug for treatment of endocrine-resistant metastatic breast cancer 








Figure 7. Basic mechanisms of SERMs, SERDs, and AIs. 1) Classic ER activation 
pathway. Estrogens activates ER, after dimerization of ER association with ERE 
occurs. Recruitment of coactivators (CoA) and transcriptional machinery (TF) leads to 
transcription. 2) ER bound by SERM. Binding of SERM promotes dimerization and 
association to ERE. SERM-bound ER recruits corepressors (CoR) and transcription is 
inhibited. 3) SERD-bound ERs cannot dimerize and therefore do not bind EREs; also, 
SERDs promote proteasomal degradation of ERs. 4) AIs prevent the conversion of 
androgens to estrogens by binding aromatase (A) leaving no estrogens available for 
activation of ERs. Modified from (72). 
 Aromatase inhibitors 1.4.2
The principle of AIs is to inhibit ER transcriptional activity by suppressing its ligand, 
E2. This is facilitated by inhibiting the aromatase enzymes that aromatize androgens to 
estrogens (androstenedione  estrone (E1), testosterone  estradiol (E2)). E1 does 
not activate the ER, and its circulating levels exceed E2 levels by a factor of 4-5, 





readily converted to E2 by dehydrogenases (73). Two classes of AIs exist and differ 
from one another in how they interact and inhibit the aromatase enzyme. Steroidal AIs 
(exemestane) are derivates of androstenedione that irreversibly bind the substrate-
binding pocket of aromatase, causing inactivation. In contrast, non-steroidal AIs 
(letrozole, anastrazole) form a reversible bond to the heme moiety of the substrate-
binding site, causing inhibition (73). In the adjuvant setting, AIs are mainly used in 
postmenopausal women. After menopause, ovarian production of estrogen ceases, and 
estrogen synthesis is restricted to the enzymatic conversion of androgens to estrogens 
in peripheral tissues. While estrogens are produced at lower concentrations in 
postmenopausal women, they continue to activate the ER and promote tumor growth, 
and AIs have proven to be effective compounds for inhibition of this process in 
postmenopausal patients (62). When given to pre-menopausal women, AIs instigate a 
feedback-loop involving increased secretion of gonadotropin and increased synthesis 
of estrogen in the ovaries. Therefore, AIs must be given in concert with gonadotropin-
releasing-hormone agonists in pre-menopausal patients (74). In postmenopausal 
women, AIs taken from the outset for at least for 2 years (23) have been shown to be 
more effective than tamoxifen at increasing relapse-free survival (62). Thereafter, 
patients may continue with AIs or tamoxifen for another 3 years, for a total of 5 years. 
In addition, 5 to 10 years on tamoxifen is a viable option for these patients, in 
particular for node-negative patients (6, 75) (see also Fig. 13). AIs have also been 
shown to have greater efficacy in the treatment of patients with postmenopausal 
metastatic breast cancer and are therefore the treatment of choice for such patients 
(23).  
 Selective estrogen receptor degraders 1.4.3
SERDs inhibit ER transcriptional activity by binding to the ligand-binding pocket of 
ER and preventing dimerization of the receptors (Fig. 7). More specifically, the 
protruding sidechain of the SERD obstructs helix 12 from interaction with the LBD, 
and the receptor is not able to adopt antagonistic or agonistic forms (72). In addition, 
as it name implies, SERDs induce degradation of the ER; however, this mechanism 





(76). Although several SERDs have been developed, fulvestrant is the only SERD 
approved for clinical use at this time. Fulvestrant has not been shown to be superior to 
tamoxifen in reducing proliferation; however its unique mechanism of ER inhibition 
represents an important treatment option for patients that have progressed on prior 
endocrine treatment such as AIs or tamoxifen (72). It has consequently become a 
useful drug in the metastatic setting, where it is approved as a first- and/or second-line 
treatment option alone or in combination with AIs or the CDK 4/6 inhibitor palbocilib 
(72).  
 Selective estrogen receptor modulators 1.4.4
SERMs bind the ER and induce the recruitment of corepressors instead of the 
coactivators that are recruited when the ER is bound by E2 (Fig. 8). More specifically, 
the binding of E2 to the ER ligand-binding pocket promotes conformational change to 
the receptor in which the ligand becomes covered by helix 12 in the LBD, which 
allows coactivators to bind to the hydrophobic groove in the AF-2 region that is 
exposed during this process (Fig. 8A). In contrast, when a SERM binds to the ligand-
binding pocket of ER, the protruding side chain of the SERM obstructs helix 12 in 
covering the molecule thus forcing a conformational change that results in the helix 12 
occupying the site of coactivator binding. In this situation, the SERM-bound ER is not 
able to recruit coactivators and instead associates with corepressors, repressing 
transcription (54, 55) (Fig 8B). The non-steroidal SERM tamoxifen was the first 
SERM to be approved for clinical use in breast cancer and remains the only SERM 
used in neoadjuvant, adjuvant, and metastatic settings. Due to variations in levels of 
coactivators and corepressors between various tissues, the antagonistic behavior of 
tamoxifen in tumor tissue is contrasted in other tissues such as the uterus, where it has 
an agonistic effect (69, 77), and tamoxifen use is consequently associated with a 
higher risk of endometrial cancer (78). Several SERMs have subsequently been 
developed in an effort to reduce the agonistic effect on the endometrium while 
preserving the anti-ER effect on tumor tissue (72). Raloxifene is the only SERM that 
meet these two criteria and has thus been approved for use in the prevention setting for 





Tamoxifen may also be used in a prevention setting, where it has been shown to 
reduce breast cancer incidence by 33% (79). In the adjuvant setting tamoxifen can 
reduce relapse by 50% (80) and mortality by 31% (12). Current guidelines for 
adjuvant tamoxifen use in Norway (6) recommend up to 10 years of treatment based 
on the findings of the ATLAS and aTTom trials, which showed improved long-term 
survival after extending treatment time from 5 to 10 years (81, 82). Depending on 
menopause status, tamoxifen may also be used in combination with ovarian 
suppression and in sequence with AIs (6, 23). In the metastatic setting, tamoxifen is 
the preferred endocrine drug in treatment of pre-menopausal patients and is often used 
in combination with ovarian ablation or suppression (23). Depending on the previous 
treatment regimens a patient has undergone, tamoxifen may also be useful as a late-











Figure 8. Mechanism of agonism and antagonism of E2 and SERM on ER. 
Binding of E2 leads to conformational shift of Helix 12 (H12) revealing binding 
motifs for coactivators (CoA), which activate the transcription process. In contrast, 
SERMs obstruct H12 rotation and thus binding of CoA. However, SERMs allow the 
binding of corepressors (CoR) with repression of gene transcription as a result. The 
phenol bound OH-groups (orange arrows) on the Z-4OHtam and Z-Endoxifen 
molecules resemble the phenol bound OH group in E2, which leads to a deeper and 
stronger binding in the ligand-binding domain of ER. Thus, active metabolites have up 
to a 100-fold increase in affinity to ER compared to tamoxifen itself.  Adapted from 








 Endocrine resistance 1.4.5
Resistance to endocrine treatment can occur from the onset of treatment (de novo 
resistance) or after a defined duration of treatment (acquired resistance). The 
mechanisms that underlie endocrine resistance have been linked to alterations in the 
ER by mutations, epigenetic modifications, and amplifications of the ESR1 gene. 
Further, over-expression or activation of membrane-bound receptor thyrosine kinases 
(RTKs) such as EGFR, HER2, HER3, insulin receptor and the insulin like growth 
factor receptor-1 are known to be involved in endocrine resistance (83). Activation of 
the RTKs leads to alterations in the PI3K/Akt/mTOR pathway, a pathway that may 
crosstalk with ER signaling, has also been identified in endocrine-resistant breast 
tumors. Importantly, perturbation of coactivators in the ER pathway, such as increased 
levels of coactivators or decreased levels of corepressors are often observed in 
endocrine resistance (84). Abnormalities in the regulation of the cell cycle is another 
factor that plays a part in endocrine resistance through abnormal activation, 
expression, or phosphorylation of the cyclin D/CDK/Rb pathway (72). Several 
promising agents that can be administered in concert with standard endocrine agents to 
combat endocrine resistance have been and are being developed, including multiple 
mTOR inhibitors and CDK4/6 inhibitors such as palbocilib. The latter, used in 
combination with an AI, was shown to double progression-free survival when 
compared to AI alone in a trial including patients with advanced metastatic disease, 
consequently leading to swift approval of the drug by the US food and drug 
administration (85, 86). In addition to the tumor-associated resistance mentioned 
above, patient characteristics may also cause resistance to the endocrine drug, 
tamoxifen. This is referred to as metabolic resistance and involves interpatient 
variability in the ability to bio-activate tamoxifen and is discussed in detail in the 





1.5 Tamoxifen metabolism 
 Tamoxifen pharmacodynamics 1.5.1
The non-steroidal compound tamoxifen, first known as ICI 46,474, is a trans isomer of 
p-β-dimethylaminoethoxy-1,2-diphenylbut-1-ene. Tamoxifen is a pro-drug that 
undergoes extensive first phase metabolism, resulting in the formation of two 
metabolites, 4-hydroxy-tamoxifen (4OHtam) (87) and 4-hydroxy-N-desmethyl-
tamoxifen (4OHNDtam/endoxifen) (88) that exhibit affinity to the ER up to 100 times 
higher than does tamoxifen itself (89, 90). The more potent anti-estrogenic action of 
these two active metabolites compared to tamoxifen itself is caused by the presence 
and position of a phenolic hydroxyl in their structures. The phenolic A ring ensures 
“deeper” binding to the binding pocket in the LBD of the ER, causing conformational 
changes in the LBD and “correct” positioning of the bulky side chain for antagonistic 
conformation of the ER (54) (Fig. 8B). The two active metabolites have similar 
affinities to the ER and similar anti-estrogenic effects on breast cancer cell 
proliferation (91). However, endoxifen is present at concentrations up to 10 times 
higher than 4OHtam and is therefore regarded as the more important active metabolite. 
In contrast to 4OHtam, endoxifen has been shown to induce proteasomal degradation 
of the ER (92) and to exhibit distinct and highly concentration-dependent effects on 
gene expression (93). However, another gene expression study comparing 4OHtam 
and endoxifen at the same concentrations (100 nM) found the two active metabolites 
have similar effects on global gene expression (94). It is important to note that 
although other metabolites such as 3-hydroxylated metabolites have been reported to 
show anti-estrogenic activity, their concentrations in vivo are generally too low to 
demonstrate any noteworthy antagonistic effect on the ER, and to this point no other 







 Tamoxifen pharmacokinetics 1.5.2
Upon oral administration, tamoxifen will follow the classic phases of metabolism of 
which the main outcome is to make the foreign molecule more water-soluble so it can 
be excreted from the body. Steady-state levels are reached within 4-8 weeks (96). 
Although some first-pass metabolism may occur in the small intestine (97), the main 
site of tamoxifen metabolism is the liver, and the focus here will be on the hepatic 
metabolism. Once tamoxifen has reached the liver, it first undergoes phase I 
metabolism involving N-oxidation, hydroxylation and demethylation by various 
members of the cytochrome P450 (CYP) family of enzymes (98) (Fig. 9). The major 
route of phase I tamoxifen metabolism is the demethylation of tamoxifen to N-
desmethyl-tamoxifen (NDtam) catalyzed primarily by CYP3A4/5, in addition to other 
CYP enzymes including CYP2D6 (98). In plasma, NDtam is found at approximately 
twice the concentrations of the mother-drug tamoxifen at steady state (99, 100). An 
alternative and minor route involves hydroxylation of tamoxifen to 4OHtam catalyzed 
by CYP2D6, CYP2C9, CYP2C19, CYP2B6 and CYP3A4 (101). Tamoxifen may also 
be N-oxidized to tamoxifen-N-oxide (tamNoX) (102) by flavin-containing 
monooxygenases and reduced back to tamoxifen by various CYP enzymes (103). As 
NDtam, 4OHtam, and tamNoX are metabolized directly from tamoxifen, they are 
referred to as primary metabolites. Other primary metabolites include 3-hydroxy-
tamoxifen and α-hydroxy-tamoxifen (98). Secondary metabolites are formed by 
further metabolism of the primary metabolites and include hydroxylation of NDtam to 
endoxifen catalyzed by CYP2D6 and demethylation of 4OHtam to endoxifen by 
CYP3A4, CYP3A5, CYP2C19, and CYP2D6 (98). Secondary metabolites such as N-
didesmethyl-tamoxifen (N,N-DDtam) and 3-hydroxy-N-desmethyl-tamoxifen (3-
OHtam) are also formed from the primary metabolites. A minor metabolite known as 
norendoxifen that is formed by demethylation of endoxifen interestingly exhibits an 
aromatase inhibition function (104); however, the clinical impact of this metabolite 
has not been determined. Phase I metabolites are further conjugated by glucuronic 
acids (88, 102) and sulfates (105) in hepatic phase II metabolism to increase the 
hydrophilic properties. These reactions are catalyzed by glucuronidases and 





or urine; however, as much as 69% of the metabolites in the bile are reabsorbed by 
enterohepatic recirculation (107, 108). In addition, tamoxifen has a highly lipophilic 
structure and has been shown to be 98% albumin-bound, which contributes to its long 
half-life (97). Another aspect to consider in tamoxifen metabolism is the formation of 
different geometric isomers (E- and Z-isomers), in which the Z-isomers exert the most 
potent anti-estrogenic activity (Fig. 9). Adding to the complexity, the position of the 
hydroxyl group on the rings of hydroxylated metabolites may also vary. For example, 
when the hydroxyl group in 4OHtam is on the secondary structure, it is expressed as 4-
prime-OHtam or 4’OHtam (Fig. 9). The Z-4’-isomers exhibit reduced binding affinity 
to the ER compared to the Z-isomers (109). Notably, in most studies on active 
tamoxifen metabolites the Z- isomer (= the active isomer) has not been separated from 
the E- and Z’-isomers.  Consequently, the collective notation ‘endoxifen’ and 
‘4OHtam’, which includes all isomers (i.e. endoxifen = Z-endoxifen + E-endoxifen + 
Z’-endoxifen) have been used.  Thus, the notations endoxifen and 4OHtam are 
generally used in this thesis. Importantly, in the two clinical papers (paper II and III) 
of the present thesis the active isomers Z-endoxifen and Z-4OHtam were selectively 






Figure 9. Overview of tamoxifen metabolites formed during first phase hepatic 
metabolism. Only isomers of 4OHtam and endoxifen are shown; other metabolites 
may also be subject to isomerism. Blue, red, orange and green lines represent 
hydroxylation, demethylation, N-oxidation, and non-enzymatic isomerization, 
respectively. Numbered arrows represent the following enzymes involved in 
generation of active metabolites and their less active isomers: 1) CYP3A4/5, 
CYP1A1/2, CYP2C9/19, CYP2D6 2) Unknown 3) CYP2D6 4) CYP3A4/5, 
CYP2C19, CYP2D6. 5) CYP2C9/19, CYP2D6, CYP3A4, CYP2B6 6) CYP2B6, 






 Tamoxifen pharmacogenomics 1.5.3
The rationale behind most pharmacogenomic studies of tamoxifen metabolism is the 
assumption that allelic variants of tamoxifen-metabolizing enzymes affect 
concentration levels of active tamoxifen metabolites.  
The majority of studies regarding the pharmacogenomics of tamoxifen have focused 
on the CYP2D6 isoform as this enzyme is pivotal in the formation of the active 
metabolite endoxifen. CYP2D6 catalyze the hydroxylation of the major metabolite 
NDtam to endoxifen and are also involved in hydroxylating tamoxifen into the other 
active metabolite 4OHtam. The CYP2D6 gene is located on a highly polymorphic 
locus, chromosome 22q13.1, and over 100 allelic variants of CYP2D6 have been 
identified (110). The polymorphisms in the CYP2D6 gene include deletions, 
duplications, and single nucleotide polymorphisms (SNPs), which may affect the 
function or expression of the CYP2D6 enzyme. A classification system is used to 
translate the polymorphisms (genotypes) into the functional activity of the enzyme 
observed in humans (phenotype) (111). In short, the system assigns an activity score 
for each allele based on the functional consequence of the polymorphism and then 
sums the score of two alleles to assign a phenotype. The phenotypes are commonly 
distinguished into four groups; poor, intermediate, normal, and ultra-rapid 
metabolizers. The allelic frequency of genes resulting in a poor metabolizer phenotype 
is reported to be as high as 5-10% in Caucasians (112), and significant differences in 
allele frequencies between racial, ethnical, and geographical groups have been 
reported (113). 
The association between CYP2D6 phenotypes and concentration levels of endoxifen is 
well established, and it is recognized that CYP2D6 genotype can explain up to 34-52% 
of endoxifen generation from NDtam (100, 114-116). In addition, it has been reported 
that CYP2D6 contributes up to 45% of 4OHtam formation from tamoxifen in human 
liver microsomes and that CYP2D6 genotype was significantly associated with 
concentrations of the metabolite (117). Significant associations between CYP2D6 
phenotype and concentrations of 4OHtam have also been reported in breast cancer 





Several other polymorphic phase I CYP enzymes contribute in the metabolic pathway 
leading to the formation of the two active metabolites (95, 120), and the 
pharmacogenetics of these enzymes has also been linked to steady-state levels of 
active metabolites. Polymorphisms in CYP2C9, an enzyme involved in the formation 
of both 4OHtam and NDtam (the precursor of endoxifen), have been associated with 
systemic concentrations of both of these active metabolites in patients receiving 
tamoxifen treatment (95, 116). CYP3A4 is involved in the same metabolic pathways 
as CYP2C9 in addition to the demethylation of 4OHtam to endoxifen. CYP3A4 
polymorphism has been shown to be a predictor of endoxifen concentrations (121) and 
tamoxifen plasma levels (122). The latter study also demonstrated a significant 
association between 4OHtam concentrations and CYP3A4 phenotype in patients with 
impaired CYP2D6 activity. CYP3A5 is an enzyme similar in structure and function to 
CYP3A4, and several activity-impairing polymorphisms have been identified in 
CYP3A5. However, no studies have shown CYP3A5 polymorphisms to be associated 
with tamoxifen metabolite concentrations in vivo. It is believed that functional defects 
in CYP3A5 may be compensated for by CYP3A4, given their very similar functions 
(123). CYP2C19 is an enzyme involved in all metabolic steps leading to formation of 
active metabolites, and the formation of 4OHtam from tamoxifen has been 
significantly associated with CYP2C19 genotypes in breast cancer patients from two 
separate studies (114, 124).  
The effect on steady-state metabolite levels by polymorphisms in enzymes responsible 
for phase II metabolism of tamoxifen has not been fully determined. Inconsistent 
results have been reported; however, two recent studies demonstrated associations 
between systemic levels of active metabolites and genetic variants of SULT1A2 (125) 
and levels of glucoronidated endoxifen and 4OHtam in plasma with allelic variants of 
Uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes (126). Significant 
association between SULT1A1 genotypes and metabolic ratios between 
NDtam/tamoxifen and NNddtam/NDtam has been shown (127).  
Finally, transporter proteins such as ATP-binding cassette sub-family B member 1 
(ABCB1) have been shown to export active metabolites out of cells (113). Although 





proteins have been reported (115), the impact of pharmacogenetics in transporter 
proteins has not been determined.  
1.6 Tamoxifen metabolism as a predictor of response to treatment 
 Pharmacogenetic evidence 1.6.1
In 2005 Goetz and colleagues provided the first evidence for a link between CYP2D6 
genotype and breast cancer outcome when they demonstrated that patients using 
tamoxifen with two non-functional alleles of CYP2D6 had a significantly higher risk 
of relapse and lower risk of hot flashes after a median follow-up time of 11.4 years 
(128). The link between outcome and the CYP2D6 genotype was replicated in a study 
two years later, demonstrating that several activity-inhibiting allelic variants of 
CYP2D6 were associated with adverse outcomes, and patients with high-activity 
variants of CYP2C19 had improved outcomes (129). More studies reporting a positive 
association between CYP2D6 phenotypes and clinical outcome followed (130, 131). 
However, studies reporting no association (132, 133) and, surprisingly, improved 
outcomes among patients with non-functional CYP2D6 alleles (134, 135) also 
emerged during these years. Concern was expressed over the lack of attention given to 
the studies reporting “negative results.” Epidemiologists claimed that all genotype-
outcome association studies performed at the time were susceptible to several biases 
and that their results must be interpreted with caution (136). At the present time, more 
than 40 articles evaluating the CYP2D6-outcome association have been published 
(111). Among the 40 articles, four studies are regarded as having potential to resolve 
the issue. These four studies include a comprehensive meta-analysis (137) and three 
retrospective analyses of the large prospective tamoxifen trials ATAC (138), BIG1-98 
(139) and ABCSG8 (140). The meta-analysis showed a positive association only when 
applying strict selection criteria, however no significant outcome association was 
found when using less strict or no inclusion criteria (137). The analyses of ATAC and 
BIG1-98 showed no association and ABSG8 applied a case-control design that 
demonstrated a positive association only during the period of tamoxifen administration 





Clinical Practice Guidelines currently do not recommend the use of CYP2D6 
polymorphisms as a biomarker for guiding adjuvant endocrine treatment selection 
(141). Associations between clinical tamoxifen efficacy and polymorphisms in other 
enzymes involved in the generation or elimination of the active metabolites have also 
been reported; however, these results are also divergent. In any case, since the 
contributions of the other enzymes to active metabolite concentrations are minor 
compared to CYP2D6, it is not plausible that these enzymes can function alone as 
biomarkers for tamoxifen efficacy.  
The lack of consistent evidence for an association between tamoxifen 
pharmacogenetics and clinical efficacy of tamoxifen may be caused by multiple 
factors. First, all clinical studies on the association between pharmacogenetics and 
outcome have been performed retrospectively on studies in which this association was 
never the primary hypothesis. Importantly, adherence to tamoxifen can be as low 50% 
over a 5-year treatment period (142-144) and adherence has not been accounted for in 
many of the pharmacogenetic studies. Co-medications commonly prescribed to breast 
cancer patients such as SSRIs have been shown to inhibit CYP2D6 and decrease 
endoxifen concentrations (99), and this effect has not been accounted for in many of 
the studies. Loss of heterozygosity is found in 40% of ER-positive breast cancers, and 
tumor DNA is not recommended for determination of germline polymorphisms unless 
special methodological considerations are taken into account (145). Several trials have 
used tumor DNA to determine CYP2D6 phenotype, while others have used germline 
DNA, and this may have added to discrepancies. Also, CYP2D6 genotype can only 
explain 50-60% of variability in endoxifen concentrations, and prediction models 
including other enzymes and factors that contribute to steady-state concentrations of 
endoxifen should also be accounted for (121). Further, the systems used to classify 
CYP2D6 phenotypes from genotype is not substrate specific for endoxifen, and the 
phenotypes produced do not predict actual concentration levels between phenotype 
groups precisely enough (146). A final reason results may differ is that there is no 
association between outcome and tamoxifen metabolism. Some models have indicated 





factor of 1,558 in activity at the receptor (147) in postmenopausal women, regardless 
of CYP2D6 genotype (136).  
 Pharmacokinetic evidence 1.6.2
Using pharmacogenetics is an indirect approach that aims to predict levels of active 
metabolites. Obviously, the direct measurement of active metabolite levels would 
circumvent many of the issues discussed in the section above. However, the main 
obstacle for this analysis has been that very few prospective tamoxifen trials have 
collected samples allowing for measurement of steady-state tamoxifen metabolite 
levels. Therefore, the investigation of this association in the adjuvant setting has to this 
point been limited to three retrospective analyses of tamoxifen treated patients and a 
recently commenced prospective trial.   
Madlensky et al. measured tamoxifen metabolite concentrations in a cohort of 1,370 
patients using tamoxifen adjuvantly originally recruited trough the women’s healthy 
eating and living (WHEL) study, a randomized controlled trial with dietary 
intervention. The study had an average follow-up time of 7.3 years, and they reported 
that patients with endoxifen levels representing the lowest quintile of endoxifen (≤16 
nM) had a higher risk of metastatic events (118). A similar threshold effect of 
endoxifen was demonstrated in a retrospective analysis of 306 pre-menopausal 
patients included in the prospective study of outcomes in sporadic versus hereditary 
breast cancer (POSH). This study included patients adjuvantly treated with tamoxifen 
and had a median follow-up time of 6.4 years. The patients were separated into 
quartiles based on their endoxifen levels, and a significant difference in distant 
relapse-free survival was identified when comparing the lowest quartile (<14.15 nM) 
with the highest quartile (>35 nM) (114). An explorative study, including 48 patients, 
used a nested case-control design to show that patients with high levels of endoxifen 
(> 187 nM) were at greater risk for recurrence (148). An additional finding was a J-
shaped relationship between endoxifen concentrations and recurrence, meaning that 
patients with very low levels (no threshold was specified by the authors) also had a 
higher risk. However, the results of this explorative hypothesis-generating study 





prospective trial has investigated the impact of endoxifen concentrations in the 
neoadjuvant and metastatic setting (149). The authors reported that no relationship 
between endoxifen concentrations and objective response rates, clinical benefit, or 
progression-free survival was identified in the neoadjuvant and metastatic setting. The 
first results of the CYPTAM trial, a prospective trial evaluating the association of 
endoxifen levels on breast cancer outcome in the adjuvant setting was recently 
presented at the ASCO conference in which no threshold effects could be observed 
(150). However, the results from this prospective trial may be premature as follow-up 
time is currently limited. Updates from this trial will certainly be interesting to follow 
in the coming years as the trial represent the only prospective trial investigating both 
genotype and active metabolite concentration association in adjuvantly tamoxifen-
treated breast cancer patients.  
The association between tamoxifen metabolite concentrations and tamoxifen efficacy 
has also been investigated in the prevention setting, in which no association could be 
demonstrated (151). However, the LC-MS/MS method used to measure tamoxifen 
metabolites in this study was later criticized for producing inaccurate and over-
estimated endoxifen levels (152).  
1.7 Discontinuation of per-oral tamoxifen treatment 
 Challenges with tamoxifen treatment  1.7.1
Tamoxifen treatment is administered orally by the patients themselves on a daily basis. 
The main challenge of this unsupervised long-term treatment (5-10 years) is low 
adherence and/or discontinuation of therapy. Adherence refers to a patients 
compliance to follow the prescription guidelines and non-adherence is generally set at 
taking less than 80% of the pills during a given period (153). The cut-off is based on 
the fact that missing a dose or two is not believed to affect treatment efficacy of 
tamoxifen due to its relatively long half-life of 2-4 weeks. Persistence is the length of 
time from start to discontinuation of therapy, and non-persistence is a synonym to 





treatment time. Thus, it is important to distinguish between non-adherence and 
discontinuation. 
In general terms, the adherence rates for tamoxifen are between 45% and 93.4%, and 
the rates for discontinuation are between 15% and 60%; patients tend to be more 
adherent at the start of the treatment compared to later (144). A meta-regression 
analysis, including more than 85,000 patients from 26 studies, on tamoxifen adherence 
showed a discontinuation rate of 47.1% at 5 years (154). However, the studies vary in 
terms of how adherence and discontinuation is measured (self-reported/prescription 
databases), both of which are susceptible to biases. Self-reported adherence represents 
the method most susceptible to bias, but also using the patients refill records to 
calculate the medication possession ratios may also not represent the actual adherence, 
as it is not given that patients withdrawing drugs from the pharmacy actually take the 
medication. Further, publications studying adherence in patients not included in 
clinical trials are generally believed to represent a more accurate picture of adherence 
compared to studies that included patients enrolled in clinical trials. This is most likely 
due to the fact that patients involved in clinical trials receive closer follow-up and 
usually represent a selection of patients that are highly motivated to participate (155).  
Two large studies using prescription databases to determine discontinuation rates 
among patients not included in clinical trials (142, 156) found that 35.2% and 38% of 
the patients had discontinued their tamoxifen treatment at 3.5 and 4.5 years, 
respectively. Similar results were obtained in a study relying on self-reported 
persistence from 435 patients not included in clinical trials; in this study 31% of the 
patients had discontinued before the end of the treatment at 5 years (157).  
It is plausible that early discontinuation of tamoxifen could represent a higher risk of 
disease recurrence, which has been shown in patients with shorter duration of 
treatment (158). Other studies have found that patients who discontinued or were non-
adherent to endocrine therapy (AIs and tamoxifen) had more early breast cancer events 
(159) and significantly poorer overall survival (160) compared to patients completing 
the treatment and remaining adherent. Increased risk of all cause of death for women 





Importantly, the results of the ATLAS (81) and aTTom (82) trials showing improved 
outcome after prolonging tamoxifen testament from 5 to 10 years, should encourage 
more focus on adherence and persistence to treatment.  
 Risk factors for discontinuation 1.7.2
The reasons for discontinuation are multifactorial and complex as several factors have 
been linked to endocrine treatment discontinuation. Comorbidities and concurrent 
treatments, financial issues, patient’s perception of risk and psychological factors such 
as anxiety and depression are factors that have been associated with risk of 
discontinuation (155, 162). The most commonly reported risk factors for quitting 
tamoxifen treatment prematurely are side effects and age. Age has repeatedly been 
significantly associated with adherence to tamoxifen therapy in which the youngest 
and the oldest patients are the ones who exhibit the poorest adherence (142, 163). Side 
effects have also been associated with non-persistence in several independent cohorts 
(143, 157, 164). Further, a recent study by Kwan et al. found that the occurrence of 
adverse events was the second most common reason (most common reason was 
menopausal status) for switching from tamoxifen to an AI among 1,143 patients with 
early breast cancer and that 22% of the patients who had switched eventually 
discontinued the treatment (165). However, data from a prospective placebo-controlled 
tamoxifen trial showed that patients using placebo were more likely to discontinue 
than patients using tamoxifen, and high portions of the placebo group reported 
experiencing side effects commonly associated with tamoxifen use such as hot flashes 
and vaginal discharge (166).  
Substantial inter-individual variability exists in the experience of side effects among 
tamoxifen users, and tamoxifen metabolism has been suggested as predictor of side 
effects. Few studies have investigated the role of tamoxifen metabolite concentrations 
(167-169) and CYP2D6 (128, 170-172) in relation to adverse events, and the results 






 Cell model 1.8.1
To study the effects of tamoxifen metabolites on gene expression in vitro, we used the 
breast cancer cell line MCF-7, short for Michigan Cancer Foundation-7, the cancer 
institute where the cell line was first isolated in 1973 (173). This adenocarcinoma cell 
line originates from a metastatic site (pleural effusion) of a 69 year old female and has 
molecular characteristics similar to the luminal A subtype of breast cancer (174), and 
the cell line is positive for ER and PR and negative for HER2 expression. Despite its 
metastatic origin, MCF-7 cells exhibit the characteristics of differentiated mammary 
epithelium with low ability for invasion and migration. The MCF-7 breast cancer cell 
line was chosen since it is a well-established in vitro model for studying the effects of 
anti-estrogens on proliferation and ER gene regulation (94, 175, 176). The cell line 
was purchased from the American Type Culture Collection (ATCC
®
) and cultured as 
recommended by the supplier. We chose to use tamoxifen metabolite concentrations 
found in tissue, and MCF-7 cells were treated with 1000 ng/mL NDtam, 100 ng/mL 
4OHtam and 1000 ng/mL endoxifen to elucidate the gene regulatory roles of these 
tamoxifen metabolites.  
 Gene expression analyses 1.8.2
  Microarray 1.8.2.1
To characterize the effect of tamoxifen metabolites on MCF-7 global gene expression, 
Illumina BeadArray Microarray Technology was utilized at the Norwegian Microarray 
Consortium core facility at the University of Bergen. This microarray technology uses 
silica beads that have thousands of oligonucleotides attached to them that are 
randomly arranged in microwells on glass or silica slides. Each oligonucleotide 
contained the complementary sequence of a specific RNA transcript (probe) and an 
address sequence allowing for identification of the probe on the array. Each bead had 
thousands of copies of one unique probe attached, and an array contained up to 44,000 
unique oligonucleotides. Total RNA from MCF-7 cells were converted to double 





transcripts. The labelled transcripts were then hybridized to the probes, and the signal 
intensity was read by the Illumina iScan System and calculated as the average of all 
beads with the same probe. The identity of each bead was determined by decoding the 
address-sequence. The signal intensity corresponded to the quantity of the specific 
gene transcript in the sample.  
Differential gene expression between the differently treated samples was analyzed 
using significance analysis of microarray (SAM) (177) method in J-express gene 
expression analysis software (178). The SAM analysis provided a ranked gene list of 
the differential gene expression between different samples. The list was ranked 
according to the Delta[i], which calculated the difference between the strength of the 
gene expression D[i] and the expected strength De[i]significance between treatment 
groups. Another important parameter in the SAM analysis is the false discovery rate 
(FDR) which corrects for multiple testing and is estimated through permutation and 
expresses the expected proportion of false positives in the list of genes. The difference 
in expression of a given gene is usually reported by the use of fold change (FC), and 
the significance of the finding is reported by the q-value, an FDR analog to the p-
value. These measures are employed when determining cut-off values to generate a 
selection of differentially expressed genes that can further be studied by bioinformatics 
such as GSEA, gene ontology and pathway analyses. These measures were employed 
in paper I to generate a list of genes in which we characterized the gene ontology using 
the PANTHER database (www.pantherdb.org) to search for statistically over-
represented ontology categories.  
  Quantitative real-time polymerase chain reaction (Q-rt-PCR) 1.8.2.2
Q-rt-PCR using the LightCycler® 480 Probes Master system was applied to validate 
differential gene expression observed in microarray analysis, as well as to characterize 
differential gene expression after estrogen deprivation and knockdown of SRC-3. In 
short, total RNA isolated from cell samples was reversibly transcribed to cDNA, 
which formed the template for the Q-rt-PCR reaction. Primers allowing for 
amplification of complementary regions of target genes were designed in silico using 
the Universal ProbeLibrary (UPL) Assay Design Center (Roche®, Applied Science). 





signals when hybridized to target PCR products. The fluorescent signal of the probe 
increased in correlation with amount of target PCR product and after a certain number 
of PCR cycles the fluorescent signal became detectable, referred to as the crossing 
point (Cp). The Cp was inversely related to the expression level of the target gene, i.e. 
low Cps indicated high level of gene expression. To normalize for inter-sample 
variations, the expression level of the target gene was normalized to the expression 
level of a reference gene that was stably expressed under various treatment conditions. 
Differential gene expression between two treatment conditions was determined by 





) and was reported as FC.  
 
 Short hairpin knockdown 1.8.3
An MCF-7 cell line with stable SRC-3 knockdown and empty vector control 
previously generated through lentiviral transduction in our group (179) was used to 
investigate if the expression of CK6 was regulated by ER. The basic principle of short 
hairpin RNA (shRNA) is sequence-specific degradation of a specific mRNA in a host 
cell of interest. ShRNA utilizes the cellular mechanism termed the RNA-induced 
silencing complex (RISC). After viral transduction the shRNA is integrated into the 
host cell’s DNA and is diced to silencing RNA (siRNA) after transcription. The 
siRNA strand is further bound by proteins and guided to the RISC complex which 
identifies and binds the complementary strand of the target mRNA. The siRNA-target 
mRNA hybrid is consequently cleaved and degraded by endogenous nucleases (180) 
leading to down-regulation of the target gene. To validate successful knockdown of 
the target gene, mRNA and protein levels of the target gene were compared between 
knock-down and control using Q-rt-PCR and Western Blots, respectively.  
 Genotyping 1.8.4
DNA obtained from whole blood samples from patients included in paper II were 
screened for 15 common allelic variants of CYP2D6 by the INFINITI® CYP450 2D6I 





fluorescently labelled and hybridized to probes that are immobilized to a chip. The 
fluorescent signals were detected and measured. Results were validated using the 
Taqman drug metabolizing enzyme assay that is a Q-rt-PCR with genotype specific 
primers. Performing genotyping on tumor tissue may produce biased results caused by 
“loss of heterozygosity” (145). This was avoided in our study as we used DNA 
collected from blood. Although we chose to use this general assay that maps the most 
common polymorphism in the CYP2D6 gene, there are several more allelic variants of 
CYP2D6 that potentially could have been screened. 
 Quantitative measurements of tamoxifen metabolites in human serum 1.8.5
To measure concentrations of tamoxifen and eight metabolites in human serum (papers 
II and III), a liquid chromatography tandem mass spectrometry (LC-MS/MS) assay 
was developed and applied. Experimental design and standard analytical methods in 
regard to development, validation, and application of the LC-MS/MS method are 
described in detail in paper II. This section focuses on some of the basic concepts of 
LC-MS/MS (Fig. 10) and specific improvements in the method that was performed in 
the two studies (papers II and III). 
Biological samples, in our case human serum, are complex and need efficient sample 
preparation (clean-up) protocols to remove interfering elements, prevent matrix effect, 
decrease ion suppression, and selectively extract the compounds of interest before the 
LC-MS/MS analysis. Sample clean-up was automated and performed using a 
Hamilton STAR pipetting robot and consisted of the addition of the internal standards 
to the sample, subsequent precipitation of the proteins with acetonitrile, and dilution in 
water and methanol to reduce ion suppression.  
Tamoxifen and eight of its metabolites were chromatographically separated using an 
Aquity Ultra Performance LC system (Waters), with a phenyl C18 column as 
stationary phase and a gradient elution of water and methanol as mobile phase. The 
separation of tamoxifen and its metabolites occurs within the column and is based on 
the affinity of the compounds to the packing material particles of the column and the 
mobile phase. A compound with high affinity to the mobile phase and low affinity to 





compound with low affinity to the mobile phase and high affinity to the column. This 
separates the compounds chemically and ensures that the compounds exit the column 
at different times where they are subjected to mass spectrometry for detection (181). 
In order for the compounds to be detected by the mass spectrometer, the liquid from 
the mobile phase is vaporized to gas-phase and the molecules are ionized (182). In our 
assay, the tamoxifen metabolites were converted to positively charged ions using an 
atmospheric pressure photoionization source (APPI). 
The LC system was coupled to a Xevo TQ-S tandem mass spectrometer (Waters). In 
short, this MS system contains three quadrupoles (QDP), and each QDP is made up of 
four parallel rods that function as “filters” detecting and separating ions based on their 
specific mass-to-charge ratio. In addition, each QDP has its specific role; the first QDP 
performs mass selection and at the same time accelerates the ions of interest towards 
QDP2 where the ions collide with neutral gas and undergo fragmentation. The 
fragmented ions are then accelerated further towards the third and last QDP (183). 
The two fragmented ions (quantify and qualify) are recorded as peaks on a computer 
in which the area under the peak and peak-height vary in proportion to the 
concentration in the samples. Concentrations were calculated using a 7-point 
calibration curve in human serum and plotting the area of the analyte adjusted with the 
area of the internal standard against the nominal concentration. 
In the time between our two studies (papers II and III) the method was modified to 
reduce sample volume requirements and improve sensitivity. The sample volume was 
decreased from 50 to 20 µL and the lower the limit of quantification was decreased for 
several analytes, including the active metabolites Z-4OHtam and Z-endoxifen. Several 
Hamilton parameters (tips, dispense speed, tube format) and the dilution factor were 
also modified. Moreover, we optimized the chromatographic separation by modifying 







Figure 10. Basic concept of the LC-MS/MS assay used for measurements of 
tamoxifen metabolites in human serum. m/z values shown are transitions for parent 
ion and daughter ion 1 and 2 for tamoxifen. m/z, mass-to-charge ratio; QDP, 
quadrupole; +, ionized compounds. Modified from (181-183).  
 Patient populations 1.8.6
The OSLO1 cohort originally consists of 920 breast cancer patients enrolled in an 
observational trial on the prognostic value of isolated tumor cells from bone marrow 
(184). The patients were recruited from five different hospitals in the Oslo region in 
Norway. Routine clinical follow up included blood sampling, clinical examination, 
mammography, and chest x-ray. Adjuvant chemotherapy regimens consisted of six 
cycles of intravenous cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and 
fluorouracil 600 mg/m2, and adjuvant endocrine therapy was 20 mg/day tamoxifen for 
5 years. Thirteen patients received high-dose chemotherapy. Three years after 
inclusion, serum was drawn from 356 relapse-free patients, and 99 operable patients 
treated with tamoxifen from this cohort were included in paper II. The fact that only 
patients that were relapse-free at 3 years were included in our study should be 





The Prospective Breast Cancer Biobank (PBCB) cohort originally consists of 
approximately 1,300 patients included in a population-based regional biobank from 
patients with breast cancer at Haukeland University Hospital and Stavanger University 
Hospital in Western Norway. The biobank began collection in 2011, and recruitment is 
ongoing. The biobank comprises blood samples and patient reported outcome 
measures from breast cancer patients at all stages, and patients are treated according to 
national guidelines (6). A population of 220 ER-positive patients using tamoxifen and 
recruited between 2011 and 2016 were included in paper III. Out of these 220 patients, 
124 patients routinely answered questionnaires every 6 months as part of their 
participation in the biobank, while the remaining 96 patients delivered one single 
questionnaire in 2016.  
 Patient reported outcome measures (PROM) 1.8.7
To estimate side effects of tamoxifen (paper III), patients filled out the following 
instruments; the functional assessments of cancer therapy-endocrine subscale (FACT-
ES) version 4 and subjective health complaints (SHC). The questionnaires were filled 
out at home without supervision from health personnel.  
FACT-ES consist of the functional assessment of cancer therapy (FACT‐B), a 
standardized quality of life measure for patients undergoing breast cancer treatment, 
with the addition of an 18-item endocrine subscale specifically developed to measure 
side effects and possible benefits of endocrine treatment for breast cancer patients 
(185). The instrument has been validated for use in breast cancer patients (185, 186) as 
well as specifically in Norwegian breast cancer patients (187). The items are presented 
as 5-point Likert-type response scales.  
The SHC instrument measures severity of 29 subjective, somatic, and psychological 
health complaints during the last month, and the instrument has shown satisfactory 
validity and reliability (188). Severity is rated on a Likert scale between 0-4, where 4 
represents the highest severity of a complaint. The instrument has recently been 
validated for use in breast cancer (189). The questionnaire was used as a supplement to 
FACT-ES to validate items similar between the two questionnaires. A maximum sum 





been reported as a cut off for experiencing more than normal health complaints (188, 
190). We applied this cut-off value in our analyses of tamoxifen metabolite 
associations and as a predictor of discontinuation. Both for the FACT-ES and SHC, we 
applied dichotomization for most items, meaning responses of 0=not at all where 
coded as “no” and all other values as “yes.” We also dichotomized the variables to not 
severe/severe, in which 0=not at all, 1=a little bit and 2=somewhat were coded as “not 
severe”. 3=quite a bit and 4=very much were coded as “severe”.  
 The Norwegian Prescription Database 1.8.8
The Norwegian Prescription Database (NorPD) from the Norwegian Institute of Public 
Health was used to measure adherence, persistence, switch of endocrine treatment, and 
discontinuation among the 220 patients (Fig. 11) (paper III). Information on amount of 
pills and time points was used to calculate adherence by the use of medication 
possession ratio (sum of days covered by prescription/number of days patient was 
observed) and the cut-off for non-adherence was set to 80%. Patients with a lapse of 
tamoxifen treatment for more than 60 days were classified as discontinuers. As the 
NorPD does not provide information on patient’s consumption of pills, these measures 
are associated with uncertainty.  
 
Figure 11. Data-flow for individual data from the pharmacies or other data sources, 
via Statistics Norway to the Norwegian prescription database and an additional data 
source, which provides data files to researchers. Figure reproduced with courtesy of 






Substantial evidence for inter-individual differences in the ability to metabolize 
tamoxifen exists. However, it has not been determined if these inter-individual 
differences are predictive of tamoxifen efficacy and toxicity. The overall aim of this 
thesis was to determine the role of active and inactive tamoxifen metabolites in regard 
to gene regulation, clinical outcome, and side effects. The specific aims were as 
follows: 
1) Elucidate the gene regulative roles of endoxifen, 4OHtam, and NDtam in MCF-7 
breast cancer cells. 
2) Determine the predictive value of CYP2D6 genotyping and direct measurements 
of active tamoxifen metabolites in serum on clinical outcome in operable breast 
cancers. 
3) Elucidate the use of serum tamoxifen metabolite concentrations as biomarkers 
for side effects. 
4) Determine the validity of using pharmacy refill data to measure adherence 
















3 Summary of results 
Paper I: “The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-
regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells” 
In this study, global gene expression analyses were performed in MCF-7 breast cancer 
cells after treatment with three tamoxifen metabolites: 4OHtam, endoxifen, and 
NDtam. When comparing expression patterns of genes in MCF-7 cells after treatment 
with endoxifen and 4OHtam, endoxifen was the treatment that led to the most 
pronounced differences in gene expression. NDtam is a tamoxifen metabolite with low 
affinity to the ER, and our results showed that this metabolite caused no significant 
difference in gene expression compared to estradiol-treated cells, further verifying its 
role as an inactive metabolite. In addition, we identified a strong down-regulation of 
all three isoforms of CK6 (KRT6 A, B, C) after endoxifen treatment compared to 
control. The three CK6 isoforms were also down-regulated after estrogen-depletion of 
the MCF-7 cells and after knockdown of the ER coactivator steroid receptor 
coactivator 3 (SRC3/AIB1), which implied an ER-dependent regulation of CK6 
expression.  
Paper II: “Serum concentrations of active tamoxifen metabolites predict long-term 
survival in adjuvantly treated breast cancer patients” 
In this retrospective, observational study comprising 86 operable breast cancer patients 
with a median follow-up time of 13.9 years, we compared the predictive value of 
CYP2D6 phenotypes and concentrations of tamoxifen metabolites on long-term 
survival. Increased serum concentrations of the two active tamoxifen metabolites Z-
4OHtam and Z-endoxifen were significantly correlated to increasing CYP2D6 activity 
of the patients. None of the remaining metabolites were correlated to CYP2D6 
phenotype. No association between the CYP2D6 phenotype and breast cancer outcome 
was identified. Cox regression analyses showed a log-linear decrease in hazard (0.25) 
for BCSS for each unit (1 nM) increase of Z-4OHtam. There was no linear association 
between BCSS and the remaining metabolites. Using supervised cut-off values 
representing low concentrations for Z-4OHtam (3.26 nM) and Z-endoxifen (9.00 nM), 





patients with Z-4OHtam levels ≤3.26 nM and Z-endoxifen levels ≤9.00 nM had 
significantly poorer outcomes compared to patients with levels above these thresholds. 
Multivariable models adjusting for age, tumor size, nodal status, histological grade, 
ER and PR status, and chemotherapy did not change the results. A Kaplan-Meier total 
log-rank test of patients re-grouped into low, intermediate, and high serum 
concentrations of Z-4OHtam and Z-endoxifen, respectively, demonstrated significant 
survival difference between these three subgroups for both metabolites. No BCSS 
events for patients with high concentrations of Z-4OHtam (>8.1 nM) and Z-endoxifen 
(>59.6 nM) were found. The same differences were also observed in the overall 
survival analysis.  
Paper III: “Drug monitoring of tamoxifen metabolites predicts vaginal dryness and 
verifies a low tamoxifen discontinuation rate from the Norwegian Prescription 
Database (NorPD) in a real-world data set of breast cancer patients.” 
In this prospective longitudinal observational study comprising 220 breast cancer 
patients treated with adjuvant tamoxifen between 2011 and 2017, we investigated the 
value of tamoxifen metabolite concentrations as predictors for side effects and 
adherence. Hot flashes, vaginal problems, joint pain, and decreased libido were the 
most common side effects in our patient cohort. There was no difference in severity or 
prevalence for any side effects between years one to three. Patients that reported 
experiencing vaginal dryness had significantly higher serum concentrations of 
tamoxifen, tam-N-ox, and Z-4’-OHtam. This was shown using the concentrations as 
quartiles and as a continuous variable. In addition, patients who reported severe 
vaginal dryness had significantly higher levels of tamoxifen compared to patients not 
experiencing severe vaginal dryness. Pharmacy refill data from the NorPD showed a 
discontinuation rate of 37% after 6.1 years and 97.2% adherence. Using drug 
monitoring, we could only identify 6% of patients who did not have measurable 
tamoxifen concentrations during a period covered by a pharmacy refill of tamoxifen. 
Kaplan-Meier analyses of the two approaches showed strikingly similar curves. 
Reporting more than normal SHC, vaginal dryness, and not using chemotherapy were 






4 General discussion 
4.1 Tamoxifen metabolites in regulation of gene expression 
Tamoxifen itself is regarded as a weak antiestrogen and is dependent on the enzymatic 
biotransformation to form the potent antiestrogens endoxifen and 4OHtam. Large 
variations in steady-state concentrations of these metabolites, in particular endoxifen, 
are found between breast cancer patients. A central hypothesis is that certain levels of 
these metabolites must be reached to achieve the full therapeutic benefit of tamoxifen. 
Both metabolites have similar affinity to the ER, but endoxifen may be found at up to 
10-fold higher concentrations compared to 4OHtam and is therefore regarded as the 
main effector of anti-estrogenic activity. However, several studies have reported that it 
is not only the concentration difference that separates the metabolites in terms of anti-
estrogenic effects. Unique effects on gene expression have been identified for 
endoxifen (93), and some reports have even suggested endoxifen may have an ER 
degradation function (92). In the first study (paper I), we investigated the effects of 
4OHtam and endoxifen on gene regulation using the 1:10 concentration ratios that 
mimicked the clinical setting. When applying a 1.5-fold change compared to control 
cut off, we found that 57% of the genes regulated by 4OHtam were also regulated in 
the same direction by endoxifen. The genes that were commonly regulated by both 
active metabolites were, in general, more strongly regulated by endoxifen. This 
observation probably reflected the 10-fold concentration difference between the 
metabolites. Gene ontology analyses indicated regulation of similar function of the 
two active metabolites, but a stronger effect from endoxifen was also observed here. A 
gene expression study using 4OHtam and endoxifen at the same concentration found 
the two metabolites had similar effects on gene expression (94). It has also been 
demonstrated that increasing doses of endoxifen leads to increasingly differential gene 
expression (93). We identified 183 unique endoxifen-regulated genes; however, we 
did not explore the uniquely endoxifen-regulated genes in separate GO analyses. This 
analysis should be performed in the future to uncover possible unique mechanisms of 





high concentrations in breast cancer patients, was also included in our analyses. 
NDtam, similarly to tamoxifen itself, is regarded as a weak antiestrogen (89, 90, 92). 
Our global gene expression analyses confirmed this perception as we found NDtam to 
cause minimal change in gene expression compared to control.  
In paper I, we also report on CK6 as a potential novel target for tamoxifen and suggest 
an ER-mediated regulation of all three isoforms of CK6. The potential clinical 
implication of this finding remains to be investigated. The possible down-regulation of 
CK6 as an unspecific response to decreased proliferation in breast cancer cells should 
be investigated. This investigation could be performed with proliferation-inhibiting 
agents that do not mediate their effect through the ER. Anti-proliferative experiments 
with breast cancer and/or normal cells that do not express ER could elucidate ERs 
putative involvement in CK6 regulation. Importantly, it should be determined if the 
effects we observed on mRNA levels translate to CK6 protein levels. Most 
importantly, experiments should be designed to examine whether down-regulation of 
CK6 is related to the anti-cancer effect of tamoxifen or if it is a potential marker for 
endocrine sensitivity. 
4.2 The value of CYP2D6 phenotypes and active metabolite concentrations as 
predictive factors of tamoxifen efficacy 
In the second study (paper II) we used breast cancer outcome endpoints to compare the 
value of tamoxifen metabolite concentrations and CYP2D6 phenotyping as predictors 
of tamoxifen efficacy. CYP2D6 phenotype can explain as much as 60% of the 
endoxifen concentrations (191-194), and as expected, we found concentrations of Z-
endoxifen significantly increased with increased CYP2D6 activity. Z-4OHtam 
concentrations were also positively correlated to CYP2D6 phenotypes; however, the 
correlation was borderline significant (p=0.05). Generation of 4OHtam from 
tamoxifen is less dependent on CYP2D6, and several additional enzymes known to be 
polymorphic contribute to its generation (Fig. 9). Polymorphism in CYP2D6 is 
therefore not regarded as a strong predictor of 4OHtam concentrations. Based on the 





endoxifen concentrations being a putative predictor for tamoxifen efficacy, a large 
number of studies have investigated the association between CYP2D6 phenotypes and 
clinical outcomes (111). As outlined in section 1.6.1, the results of these studies have 
been heterogeneous, and CYP2D6 phenotype is currently not regarded as a valid 
biomarker for tamoxifen efficacy. Our data support this decision as we could not 
identify an association between CYP2D6 phenotypes and BCSS. Several factors may 
contribute to the lack of reproducibility in the association between CYP2D6 and 
outcome. As mentioned, the rationale for using CYP2D6 phenotypes to predict 
tamoxifen efficacy is based on the notion that CYP2D6 can predict endoxifen 
concentrations. However, several other factors contribute to steady-state endoxifen 
concentrations including the contribution of other polymorphic enzymes (115, 116, 
125, 126), clinical factors such as age (195) and weight (116), and the co-
administration of CYP2D6 inhibitory drugs (99). Disregarding all these factors and 
using CYP2D6 alone as a predictor for tamoxifen efficacy, therefore, seems to be a 
naïve approach. If one is to use an indirect approach to estimate endoxifen 
concentrations, an algorithm that takes CYP2D6 phenotypes and all these variables 
into account should be created (121, 196).  
An alternative approach that circumvents these issues is to measure concentrations of 
active metabolites directly. We applied this approach and demonstrated an association 
between adverse breast cancer outcome and low concentrations of Z-endoxifen. This is 
in line with two former studies (114, 118) that also identified an association between 
low concentrations of Z-endoxifen and adverse long-term outcomes. Our results 
therefore suggest that direct measurement of active metabolites is a superior approach 
in prediction of tamoxifen efficacy compared to using the CYP2D6 phenotype. This 
notion is further strengthened by the observation that our Z-endoxifen and Z-4OHtam 
cut-off values for poor prognosis included patients from all CYP2D6 phenotypes. 
However, it should be taken into account that due to our low patient number, we had 
low power to detect differences in outcome between the CYP2D6 phenotypes. 
An original finding in our second study (paper II) is the promising predictive power of 
Z-4OHtam, which has often been overshadowed by endoxifen. Despite exhibiting 





4OHtam due the supposed 10:1 concentration ratio between the two metabolites. This 
is the reason we used the “biological concentration ratio” of 10:1 in paper I. 
Intriguingly, in paper II, we observed that the Z-endoxifen/Z-4OHtam concentration 
ratio among the patients varied from 2:1 to 9:1 (median 5:1) (unpublished data). Thus, 
the concept “biological concentration ratio” should be probably reconsidered. The 
diversity in concentration ratios of Z-endoxifen and Z-4OHtam in our study may 
explain their equal value in predicting breast cancer outcomes. In the clinical setting, 
both tamoxifen and all metabolites compete to bind to the ER simultaneously. 
Algorithms to calculate the total anti-estrogenic activity score (AAS) have been 
developed (109). However, use of AAS did not improve the ability to predict 
outcomes in paper II. Hence, we recommend using measurements of Z-endoxifen and 
Z-4OHtam in clinical monitoring of breast cancer patients.      
Three studies, including ours, have reported three different Z-endoxifen cut-off values 
associated with adverse outcomes. Saladores et al. (114) separated the patients into Z-
endoxifen level quartiles and demonstrated adverse outcome for patients in the lowest 
quartile (<14.15 nM) compared to the highest quartile (>35 nM). Madlensky et al. 
(118) identified patients with Z-endoxifen levels below 16 nM as being an at-risk 
subgroup by exploring dichotomized optimal cut-off points for a split-regression 
analysis. This concentration cut off (16 nM) corresponded closely to the lowest 
quintile in their dataset. We failed to validate Madlensky’s and Saladore`s cut offs, but 
instead identified a unique cut off for our patient population using a supervised 
approach to search for an optimal cut-off point based on the multivariate “highest 
Wald” method. Although discrepancies in the cut offs between the three studies are 
apparent, the studies all identified a sub-group of patients in the lower extremities of 
active metabolite concentrations that had adverse outcomes. As mentioned above, 
many factors influence Z-endoxifen concentrations, and as we show in paper III, the 
concentrations of Z-endoxifen may vary as much as 20% within the same patient at 
different time points. Therefore, a nanomolar-specific therapeutic threshold identified 
in one population will be challenging to replicate in an independent patient cohort. 
However, if more studies show similarly low concentrations to be associated to 





account all reported cut offs should be set. The consensus threshold should add a 
safety margin of a pre-determined amount of nanomolars to ensure capture of all 
patients at risk for under-treatment. The validated therapeutic threshold can then be 
utilized in the clinical setting by means of therapeutic drug monitoring.   
4.3 Therapeutic drug monitoring 
The goal of therapeutic drug monitoring (TDM) is to personalize and optimize 
treatment by guiding a patient’s dosing regimen based on drug concentration 
measurements. If the association between clinical outcome and steady-state tamoxifen 
metabolites could be validated, TDM would represent a promising approach to 
increasing the treatment efficacy of tamoxifen, avoiding unnecessary treatment of 
patients without response, and most importantly, avoiding under-treatment and 
reducing the number of recurrences among tamoxifen users. Further potential benefits 
of TDM may include increased compliance, dose adjustment in patients with renal or 
hepatic dysfunction (197), and detection of novel drug interactions.  
When or if a consensus threshold for active metabolites is established, TDM can be 
applied in tamoxifen users by measuring the levels of active metabolites at steady state 
by LC-MS/MS (Fig. 12). Patients with active metabolite levels below the consensus-
thresholds could be dose escalated and measured again to ensure the thresholds have 
been reached. For patients that do not reach the threshold after dose escalation, a 
switch to an alternative endocrine treatment could be advised. Another possible use of 
TDM is in safely reducing dosing in patients with severe side effects while ensuring 
threshold levels are maintained. Dose reductions may also be applicable in patients 
with very high concentrations of endoxifen, a finding indicated by Love et al. (148), to 
have a negative impact on recurrence-free survival.  
Several studies have indicated that dose escalation increases tamoxifen efficacy. A 
meta-analysis of 20 trials comprising patients with early breast cancer using tamoxifen 
for 5 years indicated a trend toward reduction of recurrence in patients using higher 
doses (30 mg or 40 mg versus 20 mg) (198). Dose relationships on anti-estrogenic 





correlation between serum and tissue concentrations of tamoxifen metabolites have 
been shown, which ensures that blood sampling of systemic concentrations are 
representative for all tissues (200). 
Recently, a TDM approach was piloted in 205 breast cancer patients using tamoxifen 
(201). Serum steady-state concentration levels of tamoxifen metabolites were 
measured, and the threshold suggested by Madlensky et al (16 nM) (118) was used as 
a putative therapeutic threshold. In this study, they found that 22% of the patients 
using 20 mg of tamoxifen had not reached the threshold and that dose escalation of 
these patients to 30 or 40 mg resulted in 96% of patients obtaining serum 
concentrations above the threshold. Importantly, no significant increase in toxicity was 
observed. Two other studies increasing doses from 20 to 30 and 40 mg based on 
CYP2D6 genotypes also showed significant increases in endoxifen steady-state 
concentrations (109, 202). Notably, the median concentration of poor metabolizers in 
one of the studies changed from 6.7 nM to 33.5 nM, thereby increasing from below to 
well above the Madlensky threshold of 16 nM, after switching from 20 mg to 40 mg 
(202). The study cohort was later expanded, and the significant endoxifen increase was 
further validated. Quality of life (QoL) parameters after dose escalation showed no 
significant move towards poorer QoL, further indicating that TDM can be safely 
practiced (171). The study had a 4-month follow-up period for evaluating side effects, 
so the findings must be validated in studies with longer follow-up times. Notably, a 
recent study also suggested that drug monitoring of tamoxifen would be cost-effective 
for health systems (203).  
In conclusion, before TDM can be implemented for tamoxifen users, a clear 
relationship between systemic concentrations of active metabolites and tamoxifen 






Figure 12. Illustration of therapeutic drug monitoring during tamoxifen 
treatment. ER, estrogen receptor; CoA, coactivator; CoR, corepressor; ERE, estrogen 
response element; UGT, Uridine 5'-diphospho-glucuronosyltransferase; SULT, 
Sulfotransferase.  
4.4 Metabolite profiling and side effects 
Tamoxifen treatment has been extended to 10 years based on results from the ATLAS 
and aTTom trials (81, 82) that showed improved outcomes after prolonged treatment. 
This is positive news, however up to 50% of patients outside clinical trials 
discontinues tamoxifen treatment before 5 years (142, 143). In the third study (paper 
III), we found a discontinuation rate of 37% using the NorPD, with a median follow-
up time of 3 years. Longitudinal drug monitoring of tamoxifen confirmed these rates. 
High discontinuation rates among tamoxifen users are particularly alarming in light of 
the benefits of prolonging tamoxifen treatment to 10 years. Determining both clinical 
and biological predictors for discontinuation is therefore warranted. We identified 





normal health complaints as significant predictors of tamoxifen discontinuation. Side 
effects have repeatedly been associated with tamoxifen discontinuation (143, 157, 204, 
205), but biological markers for prediction of which patients will experience side 
effects are scarce. Some studies have suggested a link between high levels of 
tamoxifen metabolites and the prevalence or severe side effects (167-169). We 
demonstrated that high concentrations of tamoxifen, Z-4’-OHtam, and tamNoX at year 
2 after surgery were predictive of vaginal dryness and further found vaginal dryness to 
be predictive of discontinuation. This finding may have clinical implications. Vaginal 
dryness among patients undergoing anti-hormonal breast cancer treatment is believed 
to be associated with vulvovaginal atrophy (VVA), a condition associated with 
decreased estrogenization of vaginal tissue. This is particularly relevant for AIs, which 
lower the systemic estrogen levels in a non-tissue specific manner. For tamoxifen, the 
situation is more complex as tamoxifen’s anti-estrogenic effects are tissue specific, 
and for the vaginal epithelium, tamoxifen has been reported to have both estrogenic 
and anti-estrogenic effects (206). Still, vaginal dryness is a widely reported side effect 
of tamoxifen. In our data, tamoxifen concentration itself was the strongest predictor of 
vaginal dryness, not concentrations of the active metabolites, which are the main 
inducers of the anti-estrogenic effect. One putative explanation for this is that 
tamoxifen-induced vaginal dryness could be ER independent. Tamoxifen’s lipophilic 
properties have been shown to allow for accumulation and disturbance of the function 
of phospholipid bilayer cell membranes (207, 208) and could potentially disturb the 
lubrication function of vaginal epithelial cells. Regardless of the mechanisms by which 
tamoxifen causes vaginal dryness, the symptom should be addressed as it is frequently 
noted as one of the most unpleasant side effects of hormonal treatment (209), and 
patients rarely discuss these problems with their healthcare providers (210). If the 
cause is lack of estrogen stimulation of the vaginal tissue, VVA symptoms can be 
effectively relieved by administration of vaginal estrogens. Although effective, 
oncologists do not consider this treatment to be safe for patients with hormone-
sensitive breast cancer. Non-hormonal treatments such as lubricants are commonly 
prescribed, however these treatments are only considered effective by 30% of 





in order to prevent tamoxifen discontinuation and greater risk of relapse. Monitoring 
of tamoxifen metabolite concentrations may help in early detection of breast cancer 
patients at greater risk for vaginal dryness. However, as we only found this association 


























The following conclusions can be drawn from the studies in this thesis: 
I. Based on biologically relevant concentration ratios, endoxifen was the 
tamoxifen metabolite that caused the largest effects on global gene expression 
in MCF-7 breast cancer cells when compared to NDtam and 4OHtam. This 
observation further confirms endoxifen as the most important active metabolite 
in the execution of the anti-ER effect of tamoxifen. 
II. The mRNA expression of KRT6A, B and C were down-regulated by active 
tamoxifen metabolites, estrogen deprivation, and SRC-3 knockdown in MCF-7 
breast cancer cells, suggesting that the expression of CK6 is regulated through 
the ER. 
III. Low levels of Z-endoxifen and Z-4OHtam were associated with adverse clinical 
outcome for patients using tamoxifen, while CYP2D6 phenotypes were not 
associated with breast cancer outcome. The therapeutic thresholds for these 
active tamoxifen metabolites must be probably be reached to achieve the full 
clinical anti-ER effect of tamoxifen. Considerable overlap of Z-endoxifen and 
Z-4OHtam concentrations between the CYP2D6 phenotype groups suggest that 
CYP2D6 is not a suitable biomarker for tamoxifen efficacy.  
IV. High levels of tamoxifen, tamNoX, and Z-4’OHtam serum concentrations were 
associated with vaginal dryness in breast cancer patients two years after 
surgery. TDM may be used to predict which patients will have a greater risk of 
experiencing vaginal dryness.  
V. Drug monitoring of tamoxifen metabolites confirmed the NorPD as a reliable 






6 Future perspectives 
This thesis has shed light on several aspects of the functional and clinical roles of 
active tamoxifen metabolites. The pre-clinical global gene expression patterns induced 
by NDtam, 4OHtam, and endoxifen showed that endoxifen uniquely regulated over 
180 genes (paper I). The role and functions of these genes should be further explored 
by applying gene ontology, pathway or gene set enrichment analyses of genes 
uniquely regulated by endoxifen.  Such analyses could be compared to similar 
analyses performed on genes uniquely regulated by 4OHtam to compare the 
differences in the gene regulating effects of these two active metabolites. The possible 
functional effects of reduced CK6 mRNA levels in breast cancer cells should also be 
further studied to ascertain if endoxifen-mediated down-regulation of CK6 is part of 
the anti-proliferative effects of tamoxifen or other cellular processes. As CK6 is part of 
the cytoskeleton in the cancer cell, we may speculate that such strong down-regulation 
induced by endoxifen may be a novel mechanism of the apoptotic process. We endorse 
performing an electron microscopy study of endoxifen-treated MCF-7 cells as this 
would provide more insight in the changes into the cytoskeleton structure before and 
after Z-endoxifen treatment. The strong down-regulation of CK6 was observed after 
treatment of MCF-7 cells with high levels of endoxifen (1000 ng/mL), and the 
regulation of CK6 may be dose-dependent. In paper II, we showed that patients with 
the highest Z-endoxifen levels had 100% breast cancer-specific survival. 
Consequently, studies on apoptosis and EMT processes in regard to CK6 should be 
performed with increasing doses of Z-endoxifen to elucidate dose-response patterns in 
these important cellular programs. MCF-7 cells are classified as luminal A breast 
cancer cells. Among all luminal breast cancer patients two thirds have luminal A and 
one third have luminal B cancers. Luminal B cancers comprise increased proliferation 
and therefore increased benefit from chemotherapy, while luminal A cancers do not 
(212). Obviously, it will be of great interest to investigate the role of luminal A vs. B 
status on various concentrations of Z-endoxifen and Z-4OHtam. A plausible 
hypothesis is that luminal B cancers will need higher serum concentrations of Z-





effect on micro metastases. In this scenario, TDM will offer a feasible solution for 
clinicians to meet this challenge. To investigate this, dose-response proliferation 
experiments comparing increasing doses of active tamoxifen metabolites on luminal A 
and B cell lines, could be applied.  
Before TDM of tamoxifen can be introduced to clinical situations, we need to validate 
our findings in independent patient materials. The optimal patient materials for 
validation are large randomized tamoxifen studies like ATAC (62) and BIG-1 98 (75) 
trials. However, these trials did not draw serum samples during follow-up. Therefore, 
validation must be done retrospectively in observational studies with adequate follow-
up times. Through collaboration within the breast cancer research network in Norway, 
we have recently gained access to the Secondary Adjuvant Therapy with Taxotere 
(SATT) study (184). This is a reasonable large study comprising >500 patients treated 
adjuvantly with tamoxifen with a 12-year follow-up period. This unique material 
represents an excellent opportunity to validate the association between low levels of 
active tamoxifen metabolites and poor long-term survival.  
Interestingly, among the breast cancer patients with the highest serum concentrations 
of Z-endoxifen (≥ 59.6 nM) or Z-4OHtam (≥ 8.1 nM), there were no breast cancer-
related deaths (paper II). In order to validate the clinical relevance of such high serum 
concentrations of Z-endoxifen and/or Z-4OHtam, a new prospective randomized study 
is suggested. Notably, two aspects of adjuvant endocrine systemic treatment in 
postmenopausal patients allow for such a randomized trial. First, in the BIG 1-98 trial, 
there was no difference in relapse-free survival between the AI (letrozole) arm and the 
tamoxifen arm in postmenopausal node-negative breast cancer patients (75). Secondly, 
the high fracture rate in postmenopausal Scandinavian women (213) suggests choosing 
tamoxifen over AIs is wise in lymph node-negative patients who are at low risk for 
relapse. In such a study, postmenopausal lymph node-negative breast cancer patients 
would be randomized to either AI or tamoxifen after standard primary treatment 
according to treatment guidelines (Fig. 13). All patients should be followed for 15 
years, as luminal breast cancer comprises late recurrences and deaths of breast cancer 
(27). In the tamoxifen arm, serum concentrations would be measured after 70 days, at 





least two independent blood samples should be drawn. Based on an average of the two 
measurements of tamoxifen metabolites, the patients would be grouped into three 
phenotypes: “Green patients,” comprising high serum Z-endoxifen above 59.6 nM; 
“Blue patients,” comprising serum Z-endoxifen concentrations between 9.0 and 59.9 
nM and “Red patients,” comprising low serum levels of Z-endoxifen below 9.0 nM. 
The blue and red subgroups should be further randomized into “No intervention” or 
“Incremental increase of tamoxifen dose” until Z-endoxifen > 60 nM (“Green group”). 
Final long-term survival analysis would take place at 15 years, with planned interim 
analysis at 2 years (oncological safety), 5 years (short-term survival) and 10 years 
(intermediate-term survival). Moreover, the study should be adequately powered and 
patients on tamoxifen should be regularly monitored to keep them at the desired serum 
concentration. Adherence to tamoxifen would be assessed by drug monitoring, while 
adherence to AI could be determined from NorPD (paper III). Even better, 
development of LC-MS/MS methods for AIs (anastrozole, letrozole and extemestan) 
would increase the quality of estimation of the discontinuation rate of AIs. Finally, all 
side effects should be structurally followed and reported through PROMs. Such a trial 
would also allow for verification of relationships between tamoxifen, Z-4’OHtam, and 
tamNoX metabolites and vaginal dryness (paper III) and other possible associations 
that might not have been identified in paper III. Notably, during the first 2 years we 
suggest more frequent monitoring of side effects (Fig. 13) in order to capture 






Figure 13. Randomized controlled trial of adjuvant endocrine treatment in node-
negative postmenopausal breast cancer patients: aromatase inhibitor vs TDM 
adjusted Tamoxifen. pN0, lymph node negative; Tx, treatment; R, randomization; 
nM, nanomolar; @, at; PROM, Patient Reported Outcome Measures, NorPD, 
Norwegian prescription database. 
The patient cohort in paper III originated from the ongoing PBCB project, which is a 
population-based regional observational study at Haukeland University Hospital and 
Stavanger University Hospital (214). These patients are monitored for 10+ years using 
liquid biopsies (i.e. blood and urine) every 6 months. Long-term follow up of these 
patients will ensure insight into longstanding discontinuation rates among tamoxifen 
users. Long-term adherence data on tamoxifen use is of particular clinical value now 






Tamoxifen has been in use for more than 50 years, but it still may not be the optimal 
treatment for some patients due to individual variation in its metabolism. This topic is 
the crux of this thesis and should not be ignored as 10% of the luminal patients will 
present with low serum concentrations of Z-endoxifen and Z-4OHtam. Thus, a 
considerable number of luminal breast cancer patients using tamoxifen may become 
undertreated and at higher risk of relapse. In the coming years, it is therefore of critical 
importance to provide clinical validity for the association between active tamoxifen 
metabolite concentrations and tamoxifen treatment efficacy. From there, drug 
monitoring and individualized tamoxifen dosing for the largest subgroup of breast 
cancer patients can be implemented in the clinical setting. This would be a small step 
for the medical laboratory, but a giant leap towards the ultimate goal: a reduction in 
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Tamoxifen is an anti-estrogen drug used in treatment of Estrogen Receptor (ER) positive
breast cancer. Effects and side effects of tamoxifen is the sum of tamoxifen and all its metabo-
lites. 4-Hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam,
endoxifen) both have ER affinity exceeding that of the parent drug tamoxifen. 4OHNDtam is
considered the main active metabolite of tamoxifen. Ndesmethyltamoxifen (NDtam) is the
major tamoxifen metabolite. It has low affinity to the ER and is not believed to influence tumor
growth. However, NDtammight mediate adverse effects of tamoxifen treatment. In this study
we investigated the gene regulatory effects of the three metabolites of tamoxifen in MCF-7
breast cancer cells.
Material and Methods
Using concentrations that mimic the clinical situation we examined effects of 4OHtam,
4OHNDtam and NDtam on global gene expression in 17β-estradiol (E2) treated MCF-7
cells. Transcriptomic responses were assessed by correspondence analysis, differential
expression, gene ontology analysis and quantitative real time PCR (Q-rt-PCR). E2 depriva-
tion and knockdown of Steroid Receptor Coactivator-3 (SRC-3)/Amplified in Breast Cancer
1 (AIB1) mRNA in MCF-7 cells were performed to further characterize specific effects on
gene expression.
Results
4OHNDtam and 4OHtam causedmajor changes in gene expression compared to treatment
with E2 alone, with a stronger effect of 4OHNDtam. NDtam had nearly no effect on the global
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gene expression profile. Treatment of MCF-7 cells with 4OHNDtam led to a strong down-reg-
ulation of the CytoKeratin 6 isoforms (KRT6A, KRT6B and KRT6C). The CytoKeratin 6
mRNAs were also down-regulated in MCF-7 cells after E2 deprivation and after SRC-3/
AIB1 knockdown.
Conclusion
Using concentrations that mimic the clinical situation we report global gene expression
changes that were most pronounced with 4OHNDtam and minimal with NDtam. Genes
encoding CytoKeratin 6, were highly down-regulated by 4OHNDtam, as well as after E2
deprivation and knockdown of SRC-3/AIB1, indicating an estrogen receptor-dependent
regulation.
Introduction
The Selective Estrogen Receptor Modulator (SERM) tamoxifen is used in breast cancer treat-
ment and prevention. It may act as a full estrogen agonist, partial agonist or antagonist depend-
ing on the dose, species, or target organ [1]. Tamoxifen is regarded as a pro-drug since two of
its metabolites, 4-hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen
(4OHNDtam, endoxifen), both have Estrogen Receptor (ER) affinity markedly exceeding that
of tamoxifen itself [2–4]. 4OHNDtam is considered the main active metabolite of tamoxifen
since it has 100-fold higher affinity for the ER than tamoxifen and its serum levels are 10-fold
higher than that of 4OHtam [5–9]. During steady state tamoxifen treatment the concentrations
of 4OHtam, 4OHNDtam and Ndesmethyltamoxifen (NDtam) are roughly present in serum in
concentrations 5, 50 and 150% respectively compared to that of tamoxifen [10–12]. However
in the clinical situation, these concentrations vary up to tenfold between patients using an iden-
tical daily dose, furthermore the concentrations increase by increasing age [9, 13].
Properties of tamoxifen metabolites may be studied in the ER positive human breast cancer
cell line MCF-7. The majority of in vitro studies on effects of tamoxifen are using 4OHtam as
single drug, whereas studies including 4OHNDtam as single drug are used only in few in vitro
studies. Lim et al observed that 4OHNDtam and 4OHtam have similar effects on the global ex-
pression pattern in MCF-7 cells, especially on the estrogen-regulated genes [14]. Hawse et al
also studying global gene expression in MCF-7 cells observed that 4OHNDtam molecular
mechanism of action was concentration dependent and different than that of other anti-estro-
gens [15]. High but not low concentrations of 4OHNDtam resulted in induction of cell cycle
arrest and markers of apoptosis [15]. Recently, effects of 4OHNDtam as single drug have been
examined in animal studies [16, 17] and at present clinical studies using 4OHNDtam as single
drug are underway [15]. NDtam is the major tamoxifen metabolite in serum, but due to a low
affinity to the ER NDtam is believed not to influence tumor growth and little attention has
been drawn to the compound.
The effects and side effects represent a summary of effects of tamoxifen and all its metabo-
lites. In two earlier studies where the hydroxylated metabolites were not measured, it was ob-
served that the proportion of tamoxifen and its demethylated metabolites NDtam and N-
desdimethyltamoxifen (NDDtam) in serum was higher in patients with toxicity versus those
not experiencing toxicity [18, 19]. More recent studies report that women with higher
4OHNDtam levels are more likely to report side effects [13, 20].
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In the present explorative study we examined effects of the major demethylated tamoxifen
metabolite NDtam and the hydroxylated potent metabolites 4OHtam and 4OHNDtam on
global gene expression in MCF-7 cells using concentrations that are representative for the clini-
cal situation [9, 21]. We also studied differences in effects between 4OHtam and 4OHNDtam
which may influence tumor growth and searched for genes that had the most extensive changes
in gene expression profile.
Materials and Methods
Cell culture
Michigan Cancer Foundation-7 (MCF-7) human breast adenocarcinoma cells [22] were grown
at 37°C under 5% CO2, in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum, 1% (vol/vol) penicillin/streptomycin solution and 4.5 g/liter glucose. The
MCF-7 cell medium also contained 1 μM insulin. The MCF-7 cell line is a commercial cell line
in which no ethical approval is required for experiments.
Cell treatments
Treatment of MCF-7 cells with tamoxifen metabolites. The cells were preconditioned in
phenol red-free DMEM (Invitrogen, Carlsbad, CA) containing charcoal-stripped fetal bovine
serum (HycloneTM, Thermo Fischer Scientific, MA, USA) and the above supplements, for 2
days. The cells were seeded in six-well plates at a density of 300,000 cells/ml and then treated
with 10nM E2 alone or in combination with 4OHNDtam, 4OHtam or NDtam (Table 1) for
three days. E2 and 4OHtam (>70% Z isomer) were purchased from Sigma-Aldrich (Steinheim,
Germany) and 4OHNDtam (Z/E isomers 1/1) from Sintef Materials and Chemistry (Oslo, Nor-
way). NDtam was a gift from Imperial Chemical Industries, PLC Pharmaceutical divisions (Mac-
clesfield, UK). Cells were harvested after 3 days of incubation for the microarray analysis. The
growth medium from the incubated cell cultures was collected and the concentrations of tamoxi-
fen and its metabolites determined by High Pressure Liquid Chromatography (HPLC)—Tandem
Mass Spectrometry (MS/MS) [8, 23].
Estrogen deprivation and knockdown of SRC-3 in MCF-7 cells. MCF-7 cells were
grown in alpha MEM (Lonza, Belgium) supplemented with 10% fetal bovine serum (FBS),
2 mM L-glutamine, 100 units penicillin, 100 μg streptomycin and 1 μM insulin for one day
and then grown in phenol red-free Alpha MEM supplemented with 5% charcoal-stripped FBS




Day 0 1000 100 1000
Measured
Day 1 939 72,6 609
Day 2 158 16 64,9
Day 3 119 (93–133) 6.0 (4.0–7.7) 36.6 (26.4–54.4)
Concentrations determined by High Pressure Liquid Chromatography (HPLC)—Tandem Mass Spectrometry (MS/MS). Three measurements performed at
day 3. One measurement performed at day 1 and 2.
doi:10.1371/journal.pone.0122339.t001
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for 3 days. MCF-7 cells grown for 3 days with the addition of 10 nM 17β-estradiol (Sigma)
were used as control.
Short Hairpin RNA (shRNA) lentiviral transduction was used to generate MCF-7 cells con-
taining stably integrated shRNA SRC-3/AIB1 mRNA as previously described [24]. 68% reduc-
tion in SRC-3/AIB1 mRNA expression was obtained after KD of SRC-3 (SRC-3 shRNA)
compared to the control shRNA.
Homogenization and RNA extraction
Lysates from cell samples were harvested in PBS and RNA was extracted using the RNeasy Mini
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s recommendations. Samples
were treated with the RNase-Free DNase Set (Qiagen). Amount and quality of the extracted
RNA were measured by the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies,
ThermoScientific, Waltham, MA, USA) and the Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA).
Illumina iScan system
250 ng of RNA from the cell samples treated with E2, NDtam, 4OHtam and 4OHNDtam were
biotin-labeled and amplified using the Illumina TotalPrep RNA amplification kit (Ambion,
Austin, TX, USA) and the Eppendorf Mastercycler (Eppendorf Hamburg, Germany). This pro-
cedure involves RNA being reversely transcribed, amplified and biotin-16-UTP-labeled. The
biotin-labeled cRNA was thereafter quality and quantity controlled using the Agilent 2100
Bioanalyzer and the NanoDrop ND-1000 spectrophotometer. 1500 ng of cRNA was hybridized
to the humanWG-6 v.3.0 expression BeadChip (Illumina, San Diego, CA, USA) and the fluo-
rescence of the biotin-labeled cRNA was detected using the Illumina iScan.
Microarray data extraction and analysis
Quality control and preprocessing. After scanning in the iScan reader the microarray
raw data was imported into GenomeStudio software (Illumina) which removed control probes
and produced a text file that contained the signal and detection p-values per probe for all sam-
ples. This text file was further imported into J-Express 2009 (MolMine AS, Norway) where sig-
nal intensity values were quantile normalized and logarithmically transformed (base 2) [25].
Quantile normalization removes obscuring variations that arise from differences in the prepa-
ration of the microarray samples. A Correspondence Analysis (CA) and hierarchical clustering
with Pearson Correlation as a distance measure were performed to visualize the differential ex-
pression between the four differently treated groups and analyze global trends in the data [26].
In adherence to the standards of the Microarray Gene Expression Data Society (mged) the
microarray data is publicly available at ArrayExpress under the title “Tamoxifen treatment of
MCF-7 breast cancer cells” and accession number (E-MTAB-2729).
Analyses of differentially expressed genes. To search for differentially expressed genes in
MCF-7 breast cancer cells treated with E2, NDtam, 4OHtam or 4OHNDtam a Significance
Analysis of Microarrays (SAM) [27] was applied. The SAM analysis calculates the significance
of the gene expression based on the deviation between the actual signal intensity and the signal
intensity expected by chance. To obtain manageable datasets, differentially expressed genes
were defined by q-value = 0. A rank product analysis was set up to examine if there were genes
that were more regulated by one metabolite than the other. By using this non-parametric statis-
tical method it was possible to rank the genes according to fold change and compare several
rank product lists against each other. The analysis was performed using J-express (Molmine)
and Excel (Microsoft).
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To analyze which Gene Ontology (GO) functional groups the differentially expressed genes
belonged to Protein ANalysis THrough Evolutionary Relationships (PANHTER) (dated, 15.
February, 2012) [28] was applied. PANTHER identifies which functional groups are over-rep-
resented among a selection of genes and expresses the degree of over-representation with p-val-
ues (binomal statistics). The integrated gene ontology analysis in J-Express 2012 (Molmline)
software was used to validate the findings from PANTHER. Gene lists used for PANTHER
were compared to the entire gene list from the microarray and an over-representation analysis
was performed.
Quantitative-real time-PCR
1 μg or 350 ng RNA per reaction was transcribed to cDNA using the Transcriptor First Strand
cDNA Synthesis Kit (Roche Diagnostics, GmbH, Mannheim, Germany) and further quantified
using the LightCycler480 Probes Master kit (Roche) and the LightCycler480 rapid thermal cy-
cler system (Roche). Each gene was quantified relative to reference genes TATA-binding pro-
tein (TBP), glucose-6-phosphate-1-dehydrogenase (G6PD) or peptidylprolyl isomerase A /
Cyclophilin A (PPIA) to correct for variations occurring within samples and during sample
preparations. The quantification of the genes was performed using specific Universal ProbeLi-
brary (UPL) probes and target-specific primers, designed at Universal ProbeLibrary (UPL)
Assay Design Center (Roche, Applied Science), software version 2.45 (S1 Table). The relative
quantification of the genes was performed according to manufactures protocol (Roche Applied
Science).
Results
To elucidate the gene regulative roles of the three tamoxifen metabolites 4OHtam, 4OHNDtam
and NDtam in breast cancer, we performed a microarray analysis on MCF-7 cells. The MCF-7
cells were treated with the respective tamoxifen metabolites and E2 for three days with concen-
trations intended to mimic physiological concentrations (Table 1). We used the concentration
levels found in tissues which are approximately 10 times higher than the concentrations found
in serum [29]. Although the inter-individual serum concentrations of tamoxifen and its main
metabolites vary tenfold and increase by age [9], the ratio between 4OHNDtam/4OHtam is
usually 10/1 in the individual patient [9, 21]. Therefore, we used a concentration of 4OHND-
tam ten times higher than that of 4OHtam. To analyze the differential expression on a global
level between the four compounds (E2, 4OHtam, NDtam and 4OHNDtam), a Correspondence
Analysis (CA) was performed (Fig 1). The CA, displaying global gene expression in a two-di-
mensional plot, showed that the samples treated with 4OHtam and 4OHNDtam were clearly
separated from control (E2). 4OHtam and 4OHNDtam shifted gene expression in the same di-
rection, but the shift was greater for 4OHNDtam (Fig 1). The samples treated with NDtam
were clustered closely with the E2 control suggesting limited effect on gene expression in MCF-
7 cells.
To further visualize gene expression trends in our dataset we performed a self-organizing
map analysis. This clustering analysis was performed on high level mean normalized expres-
sion values for genes with a significant expression value (q-value = 0) when comparing treat-
ment to control (E2). The results showed a stepwise regulation between 4OHtam and
4OHNDtam, where 4OHNDtam resulted in the most differential expression (Fig 2).
A Significance Analysis of Microarray (SAM) identified the differentially expressed genes
for each metabolite compared to control (E2). Only six NDtam-regulated genes met the
1.5-fold change and q-value = 0 cut-off for differential expression, but half of these genes over-
lapped with one or both of the other treatment groups (Fig 3). Of the 251 genes regulated by
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4OHNDtam and 115 regulated by 4OHtam, there were 66 overlapping genes, i.e. 57% of the
4OHtam-regulated genes were also regulated in the same direction at least 1.5-fold by
4OHNDtam. Differential expression observed in the microarray (S2–S5 Tables) was confirmed
using Q-rt-PCR on a selection of genes with high differential expression (Table 2).
In the gene list for 4OHNDtam treated cells, the cytokeratin 6 (KRT6) genes were strikingly
down-regulated compared to control (E2). KRT6A was down-regulated 9.1-fold compared to
control while KRT6B and KRT6C were down-regulated 3.3- and 4.1-fold, respectively (S3
Table). The strong down-regulation of these genes was confirmed by Q-rt-PCR (Table 2). To
further explore whether the down-regulation of the KRT6s were regulated through estrogen re-
ceptor signaling we did two separate Q-rt-PCR analyses. Firstly, we cultured the cells in absence
of E2 for 3 days and examined the expression levels of the three KRT6s by Q-rt-PCR (Fig 4).
Estrogen deprivation of the MCF-7 cells for 3 days nearly abolished the mRNA expression
of KRT6A and B. Estrogen deprivation also down-regulated the KRT6C mRNA levels, but to a
less extent than KRT6A and B. Secondly, we knocked down the ligand-dependent ER-coactiva-
tor Steroid Receptor Coactivator 3 (SRC-3), also known as Amplified in Breast Cancer 1 (AIB1)
Fig 1. Correspondence analysis showing projection of MCF-7 cell samples treated with E2, NDtam,
4OHtam and 4OHNDtam. The x-axis displays the first principle component (variance: 8.01%) and y-axis
displays the second principle component (variance: 6.959%). The MCF-7 cell samples; MCF-7 treated with
only E2 (blank circle), MCF-7 treated with E2 and NDtam (blank triangle), MCF-7 treated with E2 and 4OHtam
(black square), and MCF-7 treated with E2 and 4OHNDtam (black circle).
doi:10.1371/journal.pone.0122339.g001
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Fig 2. Self-organizingmaps displaying stepwise regulation between 4OHNDtam and 4OHtam. Self-
organizing map displaying the high level mean normalized log2 transformed signal intensities (y-axis) across
different treatments (x-axis). Each treatment has 5 parallel samples (x-axis). Figure A displays a clustering of
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(Fig 5). SRC-3/AIB1 knockdown also repressed the expression of all three KRT6s. Based on
these data, we conclude that the KRT6s are positively regulated by E2.
To inform on functions of the differentially expressed genes after treatment with the three
different metabolites (fold change 1.5, q-val = 0) we performed the Gene Ontology (GO)
analysis with PANTHER. Differentially expressed genes after treatment with 4OHNDtam and
4OHtam were largely enriched in the same GO categories (Fig 6). However, the categories are
more over-represented after treatment with 4OHNDtam compared to 4OHtam. This may re-
flect the fact that there are more genes that met the cut of criteria for the clinical applicable con-
centration (1000 ng/mL) of 4OHNDtam (82", 142#) in contrast to the lower concentration
(100 ng/mL) of 4OHtam (53", 58#). NDtam on the other hand, has no representation in PAN-
THER because the fold change of 1.5 only resulted in 3 differentially expressed genes despite
having a concentration of 1000 ng/mL. Studying specific categories in PANTHER we observed
genes belonging to the category cell cycle to be down-regulated after both treatments (4OHtam
and 4OHNDtam), while genes involved in cell adhesion were up-regulated. In addition, treat-
ment of MCF-7 cells with 4OHtam resulted in a clear down-regulation of genes involved in ap-
optosis, while treatment with 4OHNDtam resulted in both up- and down-regulation of the
apoptosis related genes. Of particular note, only 4OHNDtam showed a significant effect on
genes related to antigen processing and presentation (up-regulation). To validate our findings
in the PANTHER analysis we performed an alternative GO over-representation analysis using
down-regulated genes in a stepwise regulation where 4OHNDtam is the strongest down-regulated. Figure B
shows a clustering of up-regulated genes regulated in a stepwise regulation with 4OHNDtam being the most
up-regulated.
doi:10.1371/journal.pone.0122339.g002
Fig 3. Venn diagram showing genes uniquely regulated and regulated in the same direction after
treatment with tamoxifen metabolites.Genes included have a fold change |1.5| and q-value = 0 when
comparing tamoxifen metabolites to E2. The numbers in the overlapping circles shows the number of genes
regulated in the same direction by different treatments.
doi:10.1371/journal.pone.0122339.g003
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the integrated GO analysis software in J-Express 2012. This analysis resulted in predominantly
the same over-represented categories as in PANTHER (S6 Table).
Table 2. Validation of microarray fold change values using Q-rt-PCR.
Target gene NDtam 4OHtam 4OHNDtam
KRT6A Microarray 0.99 0.93 0.73
Q-rt-PCR 0.84 (0.52–1.07) 0.49 (0.23–1.06) 0.06 (0.05–0.08)
KRT6C Microarray 0.99 0.94 0.78
Q-rt-PCR 1.08 (0.7–1.32) 0.69 (0.24–1.40) 0.11 (0.05–0.12)
CXCR4 tv2 Microarray 0.9 0.694 0.63
Q-rt-PCR 0.68 (0.51–0.90) 0.45 (0.37–0.54) 0.35 (0.27–0.47)
SERPINA3 Microarray 0.73 0.3 0.12
Q-rt-PCR 0.64 (0.58–0.69) 0.21 (0.18–0.24) 0.07 (0.05–0.08)
GPER TV4 Microarray 0.92 0.39 0.27
Q-rt-PCR 0.85 (0.76–0.94) 0.34 (0.26–0.43) 0.24 (0.15–0.35)
CTGF Microarray 1.14 1.1 2.24
Q-rt-PCR 1.05 (0.82–1.28) 1.54 (1.26–1.83) 1.15 (0.97–1.32)
COL3A1 Microarray 1.49 2.427 2.56
Q-rt-PCR 2.03 (1.36–2.70) 5.86 (3.89–7.81) 6.11 (3.46–8.77)
IRX2 Microarray 0.91 0.64 0.43
Q-rt-PCR 0.88 (0.80–0.97) 0.48 (0.44–0.52) 0.47 (0.42–0.53)
IRX3 Microarray 0.95 0.59 0.55
Q-rt-PCR 0.85 (0.75–0.97) 0.43 (0.38–0.48) 0.42 (0.35–0.52)
IRX5 Microarray 0.97 0.64 0.57
Q-rt-PCR 0.94 (0.92–0.97) 0.55 (0.52–0.58) 0.59(0.55–0.64)
Median values of fold change (E2/treatment). Numbers in brackets are min-max values. Fold changes calculated from signal intensity (microarray) and
concentration (Q-rt-PCR). N = 6 for each treatment.
doi:10.1371/journal.pone.0122339.t002
Fig 4. KRT6mRNA expression after estrogen deprivation in MCF-7 cells.MCF-7 cells were grown in
phenol red-free Alpha MEM supplemented with 5% charcoal-stripped FBS for 3 days. Cells grown for 3 days
in presence of 17β-estradiol (10 nM) were used as control. The mRNA expression was measured by Q-rt-
PCR and the relative expression levels of each gene were related to TBP mRNA. The results presented are
mean values with SEM from 3 biological replicates.
doi:10.1371/journal.pone.0122339.g004
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To further analyze the metabolite-specific potency to regulate gene expression, we searched
for genes that were differentially expressed after treatment with 4OHtam and at the same time
more differentially expressed after treatment with 4OHNDtam (rank product analysis, fold
change1.5 for each step and q-value 0.2). These cut-off values resulted in 20 up-regulated
genes and 81 down-regulated genes, that we subjected to PANTHER analysis to evaluate their
function (S1 Fig). We found that the categories developmental processes and signaling, includ-
ing G-protein coupled receptor protein signaling pathway, were over-represented among the
down-regulated genes (fold change 0.05, S7 Table). Genes involved in neurological processes
such as sensory perception were found to be over-represented among the up-regulated genes
(S8 Table). The cancer related category apoptosis was over-represented with both up- and
down-regulated genes, represented by two up-regulated genes (TNS3, EMP1) and five genes
down-regulated (DNASE1L2, CXCR4, Gal-7, FKBP5, SGK1) (Table 3).
Discussion
In this paper, we investigated changes in global gene expression in response to three tamoxifen
metabolites: 4OHtam, 4OHNDtam and NDtam. The main findings are that 4OHNDtam and
4OHtam strongly altered global gene expression in E2 treated MCF-7-cells compared to treat-
ment with estrogen alone. The effects of 4OHNDtam and 4OHtam largely overlapped, with an
overall stronger response for 4OHNDtam. NDtam had nearly no effect. We moreover identi-
fied specific genes that responded selectively to either 4OHNDtam or 4OHtam, providing new
molecular insight into metabolite-specific effects with tamoxifen treatment. Our study, using
physiological metabolite ratios, improves our understanding of how tamoxifen may mediate its
positive and adverse effects in vivo.
Effects of NDtam and tamoxifen have previously been studied in MCF-7 cells. Reddel and
Sutherland [30], using much higher concentrations than those observed in man (7.5–10 μM),
observed that NDtam was much more potent than tamoxifen in inhibiting growth. This inhibi-
tion of cell proliferation was only partially reversed by E2 or not reversed at all. The results may
be due to direct toxic effects of NDtam and not promoted via the influence on the ER. Hawse
et al examined effects of 4OHtam, 4OHNDtam and NDtam in MCF-7cells in an extensive
study, however they did not report on results when NDtam was used as a single drug [15].
Even with high concentrations of NDtam, mimicking that observed in man during steady state
treatment, our microarray analysis clearly demonstrated that NDtam had little impact on glob-
al gene expression in E2-treated MCF-7 cells. This indicates that 4OHtam and 4OHNDtam are
the main contributors to the anti-estrogenic effects of tamoxifen. However, NDtam, as the
major tamoxifen metabolite, may still contribute to toxic effects such as crystalline retinal de-
posits, macular edema, and corneal changes that have been observed previously [31, 32].
In line with others [15, 33], we observed that treatment with 4OHtam and 4OHNDtam re-
sulted in differential gene expression in E2 treated MCF-7 cells when compared to MCF-7 cells
treated with E2 alone. A clear shift in gene expression was seen in the CA (Fig 1) after the treat-
ment with 4OHtam and 4OHNDtam, however the shift was greater for 4OHNDtam than with
4OHtam. The CA showed a shift in gene expression in the same direction for 4OHtam and
4OHNDtam. When comparing the GO of the two metabolite effects separately (Fig 6), we
found that genes in categories related to cancer processes such as intracellular signaling cascade
Fig 5. KRT6mRNA expression after knockdown of SRC-3 in MCF-7 cells. A:Quantification of SRC-3
mRNA expression in MCF-7 cells infected with shRNA targeting SRC-3 (SRC-3 shRNA) and Control shRNA.
B-D:mRNA expression of KRT6A, KRT6B and KRT6C in SRC-3 shRNA- and Control shRNAMCF-7 cells.
The expression level of each gene is relative to TBP mRNA. The results presented are mean values with
SEM from 6 biological replicates.
doi:10.1371/journal.pone.0122339.g005
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were significantly down-regulated. Categories such as cell adhesion were up-regulated by both
metabolites, whereas genes involved in cell cycle were down-regulated. In addition, genes in
the cell motion category were down-regulated by 4OHNDtam, however not significantly by
Fig 6. Functional categorization of differentially expressed genes in MCF-7 cells after treatment with tamoxifen metabolites. PANTHER was used to
search for over-represented categories in the ontology class Biological Process. A significance of microarray analysis (SAM) was applied to search for genes
that were differentially expressed after treatment with the three different tamoxifen metabolites. Genes with q-val 0 and fold change1.5 were selected
from the SAM analysis. A p-value 0.05 was used as inclusion criterion for categories. The reference column at the left of the table displays the percentage
of genes that belongs to a specific category when analyzing the whole human NCBI genome (19,911 genes), e.g. 5% of the 19,911 genes belong to the
“Apoptosis” category. The same principle goes for the other numerical columns, e.g. in the 4OHNDtam vs. E2 column there are 82 up-regulated genes and
9% of these belonged to the “Apoptosis” category. The color intensity scales are based on the statistical significance (-log p-value) of over- and under-
represented PANTHER functional categories. Red illustrates “over-represented category” where more genes than expected were found in a specific
category. Blue color illustrates “under-represented category” where less genes than expected were found. Ref, Reference genes. Arrow up, up-regulated
genes. Arrow down, down-regulated genes.
doi:10.1371/journal.pone.0122339.g006
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Table 3. Genes with differential expression after treatment with 4OHtam andmore differential expression after treatment with 4OHNDtam belong-
ing to biological process category (PANTHER).
Up-regulated Down-regulated
Developmental process VGLL1, BASP1, EMP1, KRT4 KRT6A, CXCR4, TUBA3D, EGR3, EGR2, MGP, KRT17, PRLR, IRX2,
HEY2, SIAH2, OLFM1, KRT6C, IL27RA, TUBA3D, KRT6B
System development BASP1 CXCR4, EGR3, EGR2, PRLR, MGP, IRX2, HEY2, SIAH2, OLFM1,
IL27RA
Nervous system development BASP1 CXCR4, EGR3, EGR2, IRX2, HEY2, SIAH2, OLFM1
Ectoderm development BASP1, EMP1, KRT4 KRT6A, CXCR4, EGR3, EGR2, IRX2, HEY2, SIAH2, OLFM1, KRT6C,
KRT6B
Cellular process TNS3, EMP1, KRT4, INHBB,
CAV1, GABRP
KRT6A, GPR68, RERG, CXCR4, TUBA3D, TGFA, CCBP2, Gal-7,
FXYD4, FKBP5, EGR3, EGR2, GPER, MGP, RAB31, KRT17, PRLR,
CCBP2, SGK1, Gal-7, GEM, PPP2R5A, ANXA8, OLFM1, KRT6C,
IL27RA, TUBA3D, KRT6B, OXTR, PKIB
Cell communication TNS3, INHBB, CAV1, GABRP GPR68, RERG, CXCR4, TGFA, CCBP2, FXYD4, GPER, FKBP5, MGP,
RAB31, PRLR, SGK1, GEM, CCBP2, PPP2R5A, ANXA8, OLFM1,
IL27RA, OXTR, PKIB
Signal transduction TNS3, INHBB, CAV1, GABRP GPR68, RERG, CXCR4, TGFA, CCBP2, FXYD4, GPER, FKBP5, MGP,
RAB31, PRLR, SGK1, GEM, CCBP2, PPP2R5A, ANXA8, OLFM1,
IL27RA, OXTR, PKIB
Intracellular signaling cascade RERG, RAB31, PRLR, FKBP5, SGK1, GEM, PPP2R5A, IL27RA, OXTR,
PKIB
Apoptosis TNS3, EMP1 DNASE1L2, CXCR4, Gal-7, FKBP5, SGK1, Gal-7
Cell surface receptor linked signal
transduction




CXCR4, TGFA, CCBP2, PRLR, CCBP2, IL27RA
G-protein coupled receptor
protein signaling pathway
CAV1 RERG, GPR68, CXCR4, CCBP2, GPER, CCBP2, GEM, OXTR
Reproduction STARD5, OXTR
Gamete generation STARD5, OXTR
Female gamete generation STARD5, OXTR
Metabolic process HSD17B11, GALNT12, TNS3,
TGM2, DIO1, SPINK4, CAV1
DNASE1L2, SERPINA3, NXNL2, EGR3, EGR2, FKBP5, STARD5,
LRRFIP2, SGK1, IRX2, KLK5, HEY2, PPP2R5A, ISG20, ANXA8, SIAH2,
C5orf4, NAB2, SOX3, SOX9, SERPINA5, NT5DC3, ALDH3B2, ABCA12
Primary metabolic process GALNT12, TNS3, TGM2,
SPINK4, CAV1
DNASE1L2, SERPINA3, EGR3, EGR2, FKBP5, STARD5, LRRFIP2,
SGK1, IRX2, KLK5, HEY2, PPP2R5A, ISG20, ANXA8, SIAH2, C5orf4,
NAB2, SOX3, SOX9, SERPINA5, NT5DC3, ABCA12
Lipid metabolic process TNS3, CAV1 STARD5, ANXA8, C5orf4, ABCA12
Steroid metabolic process C5orf4, ABCA12
Cholesterol metabolic process C5orf4, ABCA12
Nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process
DNASE1L2, EGR3, EGR2, LRRFIP2, IRX2, HEY2, ISG20, NAB2, SOX3,
SOX9, NT5DC3
DNA metabolic process DNASE1L2
DNA catabolic process DNASE1L2
System process BASP1, SCNN1A, EMP1,
GABRP, EYA2
RERG, FKBP5, OXTR
Neurological system process BASP1, SCNN1A, EMP1,
GABRP, EYA2
RERG, FKBP5, OXTR
Sensory perception SCNN1A, EYA2 OXTR
Sensory perception of chemical
stimulus
SCNN1A
Sensory perception of taste SCNN1A
Regulation of biological process SCNN1A
Regulation of vasoconstriction SCNN1A
doi:10.1371/journal.pone.0122339.t003
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4OHtam. Further, we found an up-regulating effect on genes related to antigen processing and
presentation, a pathway associated with the emerging hallmark of cancer [34]: evasion of im-
mune surveillance. This up-regulation was observed after treatment with 4OHNDtam, but not
with 4OHtam. It is believed that cancer cells that are weakly immunogenic, and therefore
harder to identify by the immune system, are the cells which eventually will form a solid tumor
[34]. There are several theories surrounding how the weakly immunogenic cancer cells are able
to avoid being recognized by the immune system, and how the cells became weakly immuno-
genic. For breast cancer cells this may involve down-regulation of components of the major
histocompatibility complex [35] or, as recently proposed, by releasing proteins associated with
MHC-I through exosomes [36]. Our results show an up-regulation of genes associated with an-
tigen processing and presentation of peptide or polysaccharide antigens via MHC class II. This
might represent an effect of 4OHNDtam that counteracts the evasion of immune-surveillance.
However, further studies are needed to explore this hypothesis.
The differential expression observed was generally stronger during 4OHNDtam treatment.
These results are in line with earlier studies suggesting that 4OHNDtam is the main compound
promoting the clinical effects of tamoxifen treatment [2, 37]. We further studied the stronger
regulation observed by treatment with 4OHNDtam by selecting genes that were regulated by
both metabolites, but more strongly by 4OHNDtam. In the PANTHER analysis performed on
these genes (S1 Fig, Table 3), the apoptosis category was of particular interest. There was an
over-representation of both up-regulated genes and down-regulated genes in this category. On
closer inspection the up-regulated genes (TNS3, EMP1) were positive regulators of apoptosis
[38] and 4 out of 5 down-regulated genes (CXCR4, Gal-7, FKBP5, SGK1) were negative regula-
tors of apoptosis [39–42].
An interesting finding is the strong down-regulation by 4OHNDtam of genes expressing
the different keratin 6 isoforms (KRT6a, KRT6b and KRT6c). KRT6a was the most down-regu-
lated gene in our analysis (9.1–fold), and the effect on this gene was weaker after treatment
with 4OHtam (1.8-fold decrease). The two-step validation by removal of the ligand (E2) (estro-
gen deprivation) (Fig 4) and knockdown of an important ER-coactivator (SRC-3/AIB1) (Fig 5)
also suggest that the KRT6s are positively regulated by ER. It should be noted that SRC-3/AIB1
is overexpressed in 31–64% of human breast tumors [43, 44], and has been shown to increase
the agonist properties of tamoxifen [45].
The keratins, also called cytokeratins (CKs), belong to the intermediate filament proteins
that create an insoluble dense meshwork through the cytoplasm giving structural support to
the epithelial cell. Recently, however, it was shown that CKs play a more active role in various
internal cellular survival processes (e.g. proliferation and apoptosis). These proteins may un-
dergo phosphorylation and are also part of the bridging contact between the epithelial cell and
its microenvironment [46]. CK6a is the dominant isoform in the mammary gland [47] and is
up-regulated in the proliferative basal cells in healing wound edges of the skin, indicating that
this CK is involved in cellular proliferation and migration [48]. Knockout of CK6 is associated
with reduced proliferation in the murine mammary epithelium [47]. These genes are highly
up-regulated in the basaloid molecular subtype of breast cancer demonstrated by Perou and
Sorlie [49]. Interestingly, co-expression of CK 5/6 in ER positive breast cancer tumors seems to
define a subset of patients with a more adverse prognosis [50, 51]. Therefore, the down-regula-
tion of CK6 by 4OHNDtam should be further explored in appropriate designed `bench-to-
bed`studies since it may represent a new insight in understanding of the anti-cancer action of
this active tamoxifen metabolite in ER positive breast tumors.
The present study has limitations. The standard tamoxifen metabolites used were not pure
z-isomers. In the clinical situation both isomers are present although the z-isomers dominate
[52]. Furthermore some isomerization may occur in the cultures during the study. Accordingly,
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Katzenellenbogen et al observed a facile geometric isomerization of anti-estrogens which hap-
pened in tissue cultures as well as cell free medium [53]. They found that the MCF-7 cells
mainly accumulated the trans-isomer and at the nuclear ER mainly the trans-isomer was locat-
ed. Further limitations of the study are that we studied the effects of the metabolites only at one
given concentration. It must also be taken into account that the concentration of 4OHNDtam
was 10 times higher than that of 4OHtam in order to mimic the clinical situation, so the stron-
ger regulation seen by 4OHNDtam might be a reflection of the concentration differences.
Conclusions
Conclusively, the global gene expression changes caused by 4OHNDtam treatment of estrogen
treated MCF-7 cells are stronger than those of 4OHtam when using concentrations that mimic
the clinical situation. NDtam caused only minimal effects. Genes encoding CytoKeratin 6 were
highly down-regulated by 4OHNDtam, as well as after E2 deprivation and knockdown of SRC-
3/AIB1, indicating an estrogen receptor-dependent regulation. Further studies are warranted
to elucidate possible clinical applications of this finding.
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Serum concentrations of active tamoxifen
metabolites predict long-term survival in
adjuvantly treated breast cancer patients
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Abstract
Background: Controversies exist as to whether the genetic polymorphisms of the enzymes responsible for the
metabolism of tamoxifen can predict breast cancer outcome in patients using adjuvant tamoxifen. Direct
measurement of concentrations of active tamoxifen metabolites in serum may be a more biological plausible and
robust approach. We have investigated the association between CYP2D6 genotypes, serum concentrations of active
tamoxifen metabolites, and long-term outcome in tamoxifen treated breast cancer patients.
Methods: From an original observational study comprising 817 breast cancer patients, 99 women with operable breast
cancer were retrospectively included in the present study. This cohort of patients were adjuvantly treated with tamoxifen,
had provided serum samples suitable for measuring tamoxifen metabolites, and were relapse-free at 3 years after the
primary treatment commenced. The median follow-up time from this entry point to breast cancer death was 13.9 years.
Patients were CYP2D6 genotyped and grouped into four CYP2D6 phenotype groups (Ultra rapid, extensive, intermediate,
and poor metabolizers). Tamoxifen and nine metabolites were quantified in serum (n = 86) and compared with CYP2D6
phenotype groups and outcome.
Results: Breast cancer patients with low concentrations of Z-4-hydroxy-tamoxifen (Z-4OHtam; ≤ 3.26 nM) had a breast
cancer-specific survival (BCSS) of 60% compared to 84% in patients with Z-4OHtam concentrations > 3.26 nM (p = 0.020,
log-rank hazard ratio (HR) = 3.56, 95% confidence interval (CI) = 1.14–11.07). For patients with Z-4-hydroxy-N-desmethyl-
tamoxifen (Z-endoxifen) levels≤ 9.00 nM BCSS was 57% compared to 84% for patients with concentrations > 9.00 nM
(p = 0.029, HR = 3.73, 95% CI = 1.05–13.22). Low concentrations of Z-4OHtam and Z-endoxifen were associated with
poorer survival also after adjusting for clinically relevant variables (HR = 4.27, 95% CI = 1.35–13.58, and HR = 3.70, 95%
CI = 1.03–13.25, respectively). Overall survival analysis showed similar survival differences for both active metabolites. The
Antiestrogen Activity Score showed comparable effects, but did not improve the prognostic information.
Conclusions: Patients with Z-4OHtam and Z-endoxifen concentrations lower than 3.26 nM or 9.00 nM, respectively,
showed an adverse outcome. Our results suggest that direct measurement of active tamoxifen metabolite
concentrations could be of clinical value. Validation in larger study cohorts is warranted.
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* Correspondence: hsoiland@gmail.com
Gunnar Mellgren and Håvard Søiland are equal senior authors.
†Equal contributors
2Department of Clinical Science, University of Bergen, Bergen, Norway
13Department of Surgery, Section of Breast and Endocrine Surgery, Stavanger
University Hospital, Stavanger, Norway
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Helland et al. Breast Cancer Research  (2017) 19:125 
DOI 10.1186/s13058-017-0916-4
Background
Tamoxifen is a selective estrogen receptor modulator used
for adjuvant treatment of luminal (estrogen receptor (ER)-
positive and/or progesterone receptor (PR)-positive) breast
cancer (BC) subtypes. Tamoxifen is the oldest and most
prescribed endocrine BC drug and has been shown to re-
duce BC mortality by 31% [1] and BC recurrence by 50%
[2]. Tamoxifen is a widely used endocrine adjuvant treat-
ment option among pre-menopausal BC patients, with
therapy durations of up to 10 years [3, 4]. Post-menopausal
BC patients are mainly given aromatase inhibitors (AIs) for
5 years, in combination with tamoxifen for a 3–5 year
period, or tamoxifen monotherapy for 10 years if the side
effects from AIs are too bothersome [5]. Hence, tamoxifen
is still an important drug in the management of BC. How-
ever, interpatient variability in the anti-ER response and ad-
verse effects are common. Within 15 years of primary
surgery one-third of BC patients receiving tamoxifen will
have relapsed [1].
The interpatient variability in the clinical response to
tamoxifen has been suggested to be connected to its en-
zymatic conversion into active metabolites. Several of
these activating enzymes are polymorphic, including
cytochrome P450 2D6 (CYP2D6), as combinations of
the CYP2D6 alleles have been related to various kinetic
activity levels of the enzyme. CYP2D6 is a key enzyme
in the formation of the two active metabolites, Z-4-
hydroxy-N-desmethyl-tamoxifen (Z-4OHNDtam, also
known as Z-endoxifen) and Z-4-hydroxy-tamoxifen (Z-
4OHtam) [6], and concentrations of these two active
metabolites have been found to be associated with
CYP2D6 genotypes [7, 8]. Z-endoxifen and Z-4OHtam
are 30- to100-fold more potent anti-ER inhibitors than
the mother drug tamoxifen [9]. Endoxifen is present at up
to 10 times higher plasma concentrations than 4OHtam
and is therefore regarded as the most powerful metabolite
[6]. After Goetz et al. in 2005 reported an association be-
tween the CYP2D6 poor metabolizer (PM) phenotype and
higher risk of relapse among tamoxifen users [10], several
reports have been published on CYP2D6 genotype and out-
come. However, the various studies have reported contra-
dictory results and more knowledge is required in order to
make any conclusions [11–14].
An alternative approach would be to measure the con-
centrations of the active metabolites directly in serum
and associate them with breast cancer outcomes. As the
active metabolites are strong ER ligands, their serum
levels may better reflect the functional anti-estrogenic
effects in patients treated with tamoxifen. Recently,
methods to separate the Z-isomers (Z-endoxifen and Z-
4OHtam) from the less active or inactive isomers have
been developed [15]. The additive anti-ER effect from
tamoxifen metabolites and isomers with various affinity
to the ER may also be of importance to estimate the
resultant effect of tamoxifen itself and all active tamoxi-
fen metabolites [16].
In the present study, we have determined the CYP2D6
genotypes and serum concentrations of tamoxifen and
nine metabolites in 99 BC patients with a long-term
follow-up. Our aim was to investigate the predictive
value of direct measurements of active serum tamoxifen
metabolites in patients with operable breast cancers and
to compare these results with the CYP2D6 genotyping
method. We hypothesized that the genotype approach is
inferior to direct measurement of tamoxifen metabolites
regarding prediction of prognosis, and that patients with
low serum levels of active tamoxifen metabolites will
have poorer prognosis.
Methods
In this retrospective observational study the primary ob-
jective was to compare the prognostic value of direct
measurements of tamoxifen metabolites in serum with
CYP2D6 genotyping in 99 operable breast cancer pa-
tients. The secondary objective was to investigate the as-
sociations between concentrations of active tamoxifen
metabolites and CYP2D6 phenotypes.
Patients
Between May 1995 and December 1998, 817 patients
were studied in a population-based observational
micro-metastasis study [17] in Oslo, Norway. The pa-
tients were treated according to the national guide-
lines at the time. All patients with hormone receptor-
positive tumors received 20 mg tamoxifen daily for
5 years. The tumor was defined as hormone receptor
positive if ≥ 10% of the cells were positive for ER or
PR by immunohistochemistry analysis.
From this original study population, serum was drawn
from 356 relapse-free patients 3 years after inclusion. Of
these, 99 operable BC patients comprising T1/T2 tu-
mors were adjuvantly treated with tamoxifen and in-
cluded in the present study. The demographic and
clinical characteristics are presented in Table 1. The me-
dian follow-up time for breast cancer death from this
entry time was 13.9 years (range 0.6–16.5 years). The
present study population of 99 patients did not differ
from the relapse-free cohort [17] with regard to clinical
and tumor biological variables other than the treatment
selection (Table 1).
CYP2D6 genotyping and classification of CYP2D6
phenotype groups
DNA was isolated from the blood or bone marrow using
the Gentra Puregene Blood kit (Qiagen, Hilden, Germany)
or an automated phenol-chloroform procedure. The
CYP2D6 genotype determination was performed at the
Expert Center for Pharmacogenetics, Department of
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Clinical Chemistry, Erasmus University Medical Center,
Rotterdam, The Netherlands, using the CE-IVD approved
INFINITI® CYP450 2D6I Assay (Autogenomics, Carlsbad,
CA, USA) and verified using the Taqman DME assay
(Thermo Fisher Scientific, Waltham, MA, USA) according
to validated standard operating procedures in an
ISO15189-certified laboratory. INFINITI detects 15 vari-
ant alleles (Additional file 1: Table S1) and the CYP2D6
genotypes of the patients were determined based on the
combination of wild-type (wt) and variant-type (vt) alleles
and translated into four predicted CYP2D6 phenotype
groups: ultra-rapid metabolizers (UM; gene duplication
positive, no inactive variants), extensive/normal metaboli-
zers (EM; no variants or only one decreased activity allele),
intermediate metabolizers (IM; two decreased activity al-
leles or one active and one inactive allele), and poor meta-
bolizers (PM; two inactive alleles).
Determination of tamoxifen metabolites by liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
We developed a LC-MS/MS method to quantify tamoxi-
fen and nine of its metabolites in human serum. All me-
tabolites and four de uterated internal standards were
obtained commercially (Additional file 2: Table S2).










Age at diagnosis (years)
Mean (median) 58 (56) 57 (56)
Range 34–78 28–85 0.380
Menopause status, n (%)
Pre (< 55 years) 40 (40%) 151 (42%)
Post (≥ 55 years) 59 (60%) 205 (58%) 0.710
Histology, n (%)
IDC 74 (75%) 251 (76%) 0.109
ILC 24 (24%) 69 (19%)
Other infiltrating cancer 1 (1%) 16 (5%)
Tumor size, n (%)
pT1 50 (51%) 253 (71%) < 0.001*
pT2 49 (49%) 87 (25%)
pT3 – 12 (3%)
pT4 – 0 (0%)
pTx – 3 (1%)
Tumor grade, n (%)
G1 18 (18%) 110 (31%) 0.009
G2 67 (68%) 184 (52%)
G3 12 (12%) 56 (15%)
Not reported 2 (2%) 6 (2%)
Node status, n (%)
Positive 57 (58%) 93 (71%) < 0.001
Negative 41 (41%) 257 (27%)
Not reported 1 (1%) 6 (2%)
HER2/neu status, n (%)
HER2+ 7 (7%) 36 (10%) 0.193
HER2– 89 (90%) 298 (84%)
Unknown 3 (3%) 22 (6%)
Comparison of the demographic and clinical characteristics between the patients in the present study population and 356 relapse-free patients from the original
population [17]
The present study population comprises more patients with pT2 tumors, higher grade, and node-positive status due to treatment selection
*The present study population only included operable breast cancer patients; therefore p value of tumor size comparison is between pT1 and pT2 populations
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, pT pathological tumor size
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Calibrators were created from pooled human serum of
three male and six female non-tamoxifen users to which
tamoxifen metabolites were added at seven concentra-
tions (Additional file 3: Table S3).
Serum samples (50 μl) containing tamoxifen metabo-
lites were processed using a Hamilton STAR pipetting
robot (Bonaduz, Switzerland). Serum proteins were pre-
cipitated by adding 500 μL acetonitrile containing in-
ternal standards to the samples; 350 μL of the
supernatant was evaporated to dryness under a nitrogen
flow and subsequently reconstituted in 500 μL methanol
and diluted 1 to 25 in water:methanol (20:80, v:v) before
being subjected to LC-MS/MS analysis.
An Aquity UPLC system from Waters (MA, USA) with
a thermostated column oven set at 50 °C was used to
chromatographically separate the compounds; 25 μL of
sample was injected onto a 100-mm BEH Phenyl column
with a 2.1 mm internal diameter and 1.7 μm particle size
(Waters, Milford, MA, USA). The column was developed
by a weak mobile phase (A) consisting of water, and a
strong mobile phase (B) consisting of methanol, both buff-
ered with 0.01% formic acid. All gradient steps were linear,
and the flow rate was 300 μL/min. The following gradient
was used: 0–0.5 min: 95% A and 5% B; 1 min: 65% A and
35% B; 4 min: 10% A and 90% B; 4.5–8 min: 100% B; 8.1–
9 min: 90% A and 10% B.
The LC system was coupled to a Xevo TQ-S tandem
mass spectrometer (Waters, Milford, MA, USA)
equipped with an atmospheric pressure photoionization
source (APPI). All compounds were analyzed in the
positive mode. Additional file 4: Table S4 shows reten-
tion times and compound-dependent settings for the
tamoxifen metabolites.
Validation of the LC-MS/MS method
The selectivity of the method is demonstrated in Fig. 1 as
it separated the active Z-isomers of 4OHtam and endoxi-
fen from its less active Z’-isomers and inactive E-isomers.
Total analytical run-time was 9 min and the sample vol-
ume of serum was 50 μL. Accuracy and imprecision was
well within the acceptance criteria defined by regulatory
guidelines (Food and Drug Administration (FDA), Rock-
ville, MD, USA; 2002). The method was linear for all ana-
lytes (Additional file 5: Table S5). For medium
concentrations, imprecision (intra- and inter-day CV %)
was within 9% and accuracies were in the range 95–106%
(Additional file 3: Table S3) for all metabolites except cis-
β-OHtam and z-α-OHtam, which had imprecision within
15% accuracies in the range 87–109%. Cis-β-OHtam and
z-α-OHtam were not detected in patient samples.
Data analyses and statistics
SPSS statistical software, version 23 (SPSS, Inc., Chicago,
IL, USA), and MedCalc for Windows, version 16.4.3
(MedCalc Software, Ostend, Belgium), were used for the
basic statistical calculations.
Supervised cut-off values for Z-endoxifen (9.00 nM),
Z-4OHtam (3.26 nM), and Antiestrogenic Activity Score
(AAS) (16.7) were identified by multivariable Cox ap-
proach as described in Additional file 6.
Fig. 1 MRM transitions of tamoxifen and its metabolites. The chromatograms are obtained by analyzing the second point of the calibration curve.
The chromatographic separation of isomers of 4OHtam and endoxifen are shown in the lowest and second lowest panels, respectively. APPI atmospheric
pressure photoionization, MRMmultiple reaction monitoring
Helland et al. Breast Cancer Research  (2017) 19:125 Page 4 of 13
The present study included patients that had survived
the first three 3 years after surgery without experiencing
any relapse. The analysis is thus conditional on 3 year
relapse-free survival, and in the survival analysis 3 years
after surgery is used as the time origin to partially ad-
dress the pitfall of immortal person time bias [18–20].
Breast cancer-specific survival (BCSS) was defined as the
time from the primary surgery until death from breast
cancer. Cause of death was provided from the hospital
records, and in a few cases also by information from the
patient's general physician.
Survival estimates were calculated by the Kaplan-Meier
method. Univariable tests for survival differences in cat-
egorical variables were performed by the log-rank test or
the log-rank test for trend as appropriate. Multivariable
regression analysis for clinically relevant variables was per-
formed using the Cox proportional hazards method. Chi-
square, Mann-Whitney U test or Kruskal-Wallis were
used for comparisons between groups as needed. Fisher’s
exact test was used when appropriate. Two-tailed P values
< 0.05 were considered statistically significant.
To estimate the resultant ER blockade of tamoxifen
itself and the various active tamoxifen metabolites we
used the AAS as previously described [16]. In short,
the estimation of the AAS was based on the serum
concentrations of the various active tamoxifen
metabolites and their relative affinity to the ER by the
following algorithm: 0.01 × [Tamoxifen] + 1 × [Z-endox-
ifen + Z-4OHtam] + 0.1 × [Z′-endoxifen + Z′-4OHtam].
Results
CYP2D6 genotyping and quantification of tamoxifen
metabolites in serum
CYP2D6 allele frequencies are shown in Additional file
7: Table S6 and the most frequent genetic variants *1, *2,
*4 and *41 were in Hardy-Weinberg equilibrium (HWE).
The frequency of the remaining 5 alleles (*3, *5, *6, *9,
and *10) were too rare in our study cohort to perform a
HWE calculation. Ninety-one patients were successfully
CYP2D6 genotyped and the phenotypes were distributed
as follows: 4 (4.4%) ultra-rapid metabolizers, 43 (47.3%)
extensive/normal metabolizers, 36 (39.6%) intermediate
metabolizers, and 8 (8.8%) poor metabolizers. Eight pa-
tients were excluded from CYPD6 analysis due to inad-
equate volumes of blood/bone marrow for DNA
extraction or because of poor quality of DNA.
Concentrations of tamoxifen and nine metabolites
were measured using LC-MS/MS. All patient serum
samples were run in duplicate (Table 2). The mean and
median concentrations of tamoxifen and the nine me-
tabolites for the 86 patients are shown in Table 2. Cis-β-
OHtam and z-α-OHtam were included for separation of
the hydroxylated metabolites [21] and were not detect-
able in patient samples. As shown before [22], large
inter-individual variations in the concentrations of tam-
oxifen metabolites were observed between patients
(Table 2). Thirteen patients had concentrations below
the lower limits of quantification (LLQ) for tamoxifen
and all the nine metabolites. These patients were
regarded as non-adherent and excluded from the present
study, leaving 86 patients for further analyses.
Associations between CYP2D6 phenotype groups and
concentrations of tamoxifen metabolites
The median values for all metabolite concentrations
stratified by CYP2D6 phenotype groups are shown in
Additional file 8: Table S7. An association between de-
clining concentration levels and decreased CYP2D6
function was observed for Z-4OHtam and Z-endoxifen
(p = 0.05 and p < 0.001, respectively; Kruskal-Wallis)
(Fig. 2). Notably, there is a wide spread of levels of active
metabolites within each CYP2D6 phenotype group and
also a considerable overlap between them; for example,
use of the 3.26 nM (red line) and 8.13 nM (green line)
cut-off values for Z-4OHtam will include patients from
three CYP2D6 phenotype groups (Fig. 2). None of the
other metabolite concentrations showed an association
with CYP2D6 phenotype.
Breast cancer outcome in association with CYP2D6
phenotype and active tamoxifen metabolite
concentrations
To investigate the association between CYP2D6 pheno-
type and survival, a Kaplan-Meier linear trend analysis
comparing the survival of the four CYP2D6 phenotype
groups (UM, EM, IM, and PM) was performed (Fig. 3).
No significant association was observed (p = 0.966, total
log-rank). However, using EM as a reference we
achieved 80% power to detect hazard ratios (HRs) of 3.3,
10, and 35 for IM, PM, and UM, respectively. Therefore,
the result should be interpreted with care. Notably, the
excluded non-adherent patients (n = 13) were evenly dis-
tributed among the various CYP2D6 phenotype groups,
and including them did not change the results.
A Cox log-linear trend analysis controlling for age,
tumor size, grade, node status, ER, PR, and chemotherapy
was performed to investigate the association between con-
centrations of tamoxifen metabolites and outcome. We
identified a log-linear relationship between Z-4OHtam
and BCSS (p = 0.044, HR = 0.75, 95% confidence interval
(CI) = 0.56–0.99), indicating a 0.25 reduction in hazard for
each unit (1 nM) increase in Z-4OHtam. There was no
log-linear association between Z-endoxifen or the
remaining metabolites and breast cancer outcome. We
further wanted to explore the possibility of an association
between survival and concentration thresholds for the
active metabolites Z-4OHtam and Z-endoxifen. We
identified supervised cut-off values representing low
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concentrations for Z-4OHtam (3.26 nM) and Z-endoxifen
(9.00 nM) as described in the Methods section and per-
formed univariable survival analyses (Fig. 4a and b). For
Z-4OHtam the BCSS was 60% vs. 84% for the ≤ 3.26 nM
and > 3.26 nM groups, respectively (p = 0.020; log-rank
HR = 3.56, 95% CI = 1.14–11.07). For Z-endoxifen we
observed a BCSS of 57% vs. 84% for the ≤ 9.00 nM and >
9.00 nM groups, respectively (p = 0.029; log-rank HR =
3.73, 95% CI = 1.05–13.22). Adjustment for age, tumor
size, nodal status, histological grade, ER and PR status,
and chemotherapy given left Z-4OH tam and Z-endoxifen
as the only factors in the final models with HR = 4.27
(95% CI = 1.35–13.58) and HR = 3.70 (95% CI = 1.03–
13.25), respectively.
The Z’ isomers of the active metabolites also have
anti-estrogenic activity and, since our LC-MS/MS was
able to measure the Z and Z’ isomers of 4OHtam and
endoxifen separately, we were able to calculate the AAS
score (as described in Additional file 6). We further
identified threshold values representing patients with
low and high AAS and showed a BCSS of 57% for pa-
tients with AAS ≤ 16.7 compared to 84% in patients with
ASS > 16.7 (p = 0.026, HR = 3.81, 95% CI = 1.07–13.56)
(Additional file 9: Figure S1). Adjusting for the same
variables as mentioned above, AAS was the only factor
associated with BCSS (p = 0.041, HR = 3.80, 95% CI =
1.06–13.64). We also investigated the possible effect on
outcome from tamoxifen itself, the two Z’-isomers alone,







Tamoxifen 322.2 (287.5) 6.61 45.46
NDtam 723.2 (689.0) 9.55 44.75
Z-4OHNDtam 30.11 (28.15) 6.46 59.01
4'OHNDtam 30.08 (28.13) 8.18 38.09
Z-4OHtam 5.67 (5.30) 6.03 42.32
4'OHtam 7.64 (7.20) 7.54 39.34
Tam-N-ox 119.6 (97.52) 11.04 60.12
NNDDtam 92.69 (81.17) 11.14 50.80
cis-β-OHtam ND – –
z-α-OHtam ND – –
Samples were run in duplicate
Thirteen patients with metabolite levels below the limit of detection are not included in the calculations, leaving 86 patients for further analysis
Analytical CV % indicates average CV between two replicate samples for all patients
CV coefficient of variation, ND not detected
Fig. 2 Z4OHtam and Z-endoxifen concentrations compared by CYP2D6 phenotype groups. Impaired CYP2D6 function correlates with lower levels
of Z-4OHtam and Z-endoxifen (p = 0.05 and p <0.001, respectively; Kruskal-Wallis). Cut-off values representing patients with high levels (green line)
and low levels (red line) of active metabolites are shown. EM extensive metabolizer, IM intermediate metabolizer, PM poor metabolizer,
UM ultra-rapid metabolizer
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and the various non-active metabolites. No significant
thresholds were identified.
In the analysis for overall survival (OS), Z-4OHtam, Z-
endoxifen, and AAS were all significant in the univari-
able analysis (Table 3). When adjusting for the various
clinico-pathological variables, tumor size, nodal status,
and chemotherapy were added to the final models
(Table 4).
The significant linear trend observed for Z-4OHtam
encouraged us to also assess survival effects for very
high levels of active metabolites. We therefore arbi-
trarily used the concentrations corresponding to the
median concentrations for Z-4OHtam and Z-
endoxifen ultra-rapid metabolizers (UM) as cut-off
values, i.e., 8.13 nM and 59.59 nM, respectively
(Fig. 2). Hence, patients were re-grouped into low,
intermediate, and high serum concentrations of Z-
4OHtam and Z-endoxifen, respectively (Fig. 4c and d).
The Kaplan-Meier log-rank trend test demonstrated
significant survival differences between these three sub-
groups for both metabolites (Z-4OHtam, p = 0.010; Z-
endoxifen, p = 0.026) with no BCSS events for patients
with high concentrations of active metabolites (Fig. 4c
and d). The same differences were also observed in
the overall survival analysis (Z-4OHtam, p = 0.002; Z-
endoxifen, p = 0.014; log-rank trend) (Fig. 4e and f ).
Notably, the distribution of all the adjusted clinic-
pathological variables were equal between the low and
the high serum concentration subgroups.
Discussion
In the present study we identified an association be-
tween CYP2D6 phenotype groups and the serum levels
of active metabolites (Z-4OHtam and Z-endoxifen).
However, we did not find an association between
CYP2D6 phenotypes and breast cancer outcome (Fig. 3).
The low power to detect a relevant survival difference
between the CYP2D6 phenotype groups (i.e., HR be-
tween 1.5 and 2.5) is a possible explanation for its absent
prognostic value in the present study. We further inves-
tigated the association between concentrations of active
metabolites and breast cancer outcome, and this is to
our knowledge the first study to report a relationship
between low levels of the active tamoxifen metabolites
and higher risk of breast cancer death (Fig. 4). The
long follow-up time in our study allowed the use of
breast cancer-specific survival as the clinical endpoint.
We identified threshold values representing low and
high levels of active metabolites. Notably, these cut-
off values included patients from all CYP2D6 pheno-
type groups suggesting that the genotype approach
results in grouping of patients with heterogeneous
serum levels of active metabolites (Fig. 2).
To our knowledge, only three studies have analyzed
the association between tamoxifen metabolite concentra-
tions and relapse of breast cancer [23–25]. Madlensky et
al. found a 30% higher risk of relapse in patients with
low endoxifen levels (<16 nM) in patients grouped ac-
cording to endoxifen quintiles [23]. In a recent study, a
higher risk of distant relapse was observed in patients
with low (<14.15 nM) vs high (>35 nM) Z-endoxifen
levels when splitting the patients into endoxifen quar-
tiles [24]. Both studies reported that the lowest quintile/
quartile had the worst outcome, whereas the highest
quintile/quartile had the best outcome. Thus, it seems
that the use of active metabolite thresholds creates re-
producible results in survival analyses probably due to
grouping of patients that are homogeneous regarding
the anti-ER effect. This is in line with our results since
we also observed a favorable survival in breast cancer
patients with high serum metabolite levels. Our high
cut-off value is equal to the median concentrations of
active metabolites in the UM group (Fig. 2), and other
studies have shown that UM groups are often reported
to be in the best prognostic range in the subgroup ana-
lyses [26]. In a third study, no association was found be-
tween endoxifen levels and breast cancer outcome in
patients receiving low doses of tamoxifen (1 mg, 5 mg,
and 10 mg) [25]. However, the authors speculate that
sensitivity issues for detecting differences at very low
concentrations may have clouded the results. In
addition, preliminary results presented at ASCO 2016
[27] showed no association between endoxifen concen-
trations and BC outcome. However, this study included
Fig. 3 Kaplan-Meier plot of BCSS for CYP2D6 phenotypes. Patients
are grouped according to CYP2D6 phenotype group as indicated by
the colored lines. Time starting at 3 years after surgery. EM extensive
metabolizer, IM intermediate metabolizer, PM poor metabolizer, UM
ultra-rapid metabolizer
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patients receiving 20 mg tamoxifen in the metastatic
setting or as neoadjuvant treatment, a very different
context often with developed endocrine resistance.
Hence, this patient group is difficult to compare with
the operable patients undergoing adjuvant tamoxifen
treatment in our study. Interestingly, in a phase I
study administering oral Z-endoxifen 160 mg daily in
endocrine refractory metastatic breast cancer patients
[28] the response rate on the tumor was 26% and the
side effects were tolerable, with endoxifen concentra-
tions up to 5200 nM maintained over 28 days. This
study suggests that the concentrations of the active
metabolites may be important for the apoptotic effect
on breast cancer cells [28].
Fig. 4 Kaplan-Meier plots of BCSS and overall survival for concentrations of active tamoxifen metabolites. Patients are grouped according
to concentrations of active metabolites as indicated by colored lines. Time starting at 3 years after surgery. a,b BCSS for Z-4OHtam and
Z-endoxifen at concentrations above and below 3.26 nM and 9.00 nM, respectively. c,d BCSS for Z-4OHtam and Z-endoxifen at three
serum concentrations: low, intermediate, and high levels, as shown in the figure. e,f Overall survival for Z-4OHtam and Z-endoxifen at the
same three concentrations as shown in c and d. HR hazard ratio
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Here, we report for the first time an association be-
tween Z-4OHtam and BC outcome. Although endoxifen
is present at higher serum concentrations than Z-
4OHtam, their affinity to the ER is the same. Cross
tabulation between Z-endoxifen (cut-off 9.0 nM) and Z-
4OHtam (cut-off 3.26nM) shows that 50% of patients
below the Z-4OHtam threshold were not identified by
the Z-endoxifen threshold (Additional file 10: Table S8).
This implies that measuring Z-4OHtam may be of clin-
ical value. The Z’-isomers of the active metabolites also
have a certain antiestrogenic effect. After calculation of
tamoxifen and all active metabolites by means of the
AAS score, we observed a significant association be-
tween low AAS score and worse BCSS (Additional file 9:
Figure S1). However, using the AAS score was not su-
perior to the use of Z-endoxifen and Z-4OHtam
Table 3 Univariable survival analyses of breast cancer-specific survival and overall survival
Breast cancer-specific survival Overall survival
Factor Event/at risk HR 95% CI P Event/at risk HR 95% CI P
Tumor size
pT1 7/44 1 11/44 1
pT2 9/42 1.47 0.55–3.96 0.439 16/42 1.70 0.79–3.67 0.169
Node status
pN0 4/33 1 9/33 1
pN+ 12/52 2.00 0.64 –6.19 0.222 18/52 1.33 0.60–2.96 0.484
Histological grade
1 3/16 1 6/16 1
2 10/57 0.94 0.26–3.42 0.924 16/57 0.76 0.30–1.94 0.564
3 3/11 1.48 0.30–7.35 0.631 5/11 1.30 0.40–4.28 0.661
Histological grade
1 + 2 13/73 1 22/73 1
3 3/11 1.56 0.44–5.46 0.335 5/11 1.61 0.61–4.25 0.335
Age
< 55 years 7/35 1 7/35 1
≥ 55 years 9/51 0.93 0.35–2.51 0.890 20/51 2.09 0.89–4.95 0.085
ER
≥ 10% 15/75 1 26/75 1
< 10% 1/7 0.63 0.08–4.73 0.646 1/7 0.36 0.05–2.65 0.294
PR
≥ 10% 11/55 1 17/55 1
< 10% 4/27 0.72 0.23–2.25 0.566 9/27 0.98 0.43–2.19 0.951
Chemotherapy*
Yes 6/30 1 6/30 1
No 10/56 0.93 0.34–2.57 0.893 21/56 1.97 0.80–4.89 0.135
AAS
> 16.7 13/79 1 21/79 1
≤ 16.7 3/7 3.81 1.07–13.56 0.026 6/7 5.37 2.14–13.51 < 0.001
Z-4OHtam
> 3.26 nM 12/76 1 20/76 1
≤ 3.26 nM 4/10 3.56 1.14–11.11 0.020 7/10 4.05 1.70–9.64 0.001
Z-endoxifen
> 9.00 nM 13/79 1 22/79 1
≤ 9.00 nM 3/7 3.73 1.05–13.23 0.029 5/7 4.03 1.51–10.74 0.003
* Did the patients receive chemotherapy according to the treatment guidelines at the time
AAS antiestrogenic activity score, CI confidence interval, ER estrogen receptor, HR hazard ratio, pN pathologic node status, PR progesterone receptor, pT pathologic
tumor size
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concentrations, strengthening previous observations that
Z-endoxifen and Z-4OHtam are the most active tamoxi-
fen metabolites. In line with our results, a recent study
showed an aggregate effect of tamoxifen and three me-
tabolites on breast cancer relapse [29] without providing
additional prognostic information compared to the use
of endoxifen levels alone.
Our supervised threshold for low concentrations of
endoxifen identified in the present study (9.00 nM) is
slightly lower compared to the un-supervised thresh-
olds identified in previous studies (16 nM and 14.15
nM) [23, 24]. Using these cut-off values in the
present study, we observed the same pattern with
poorer survival for the lower concentration groups;
however, significance was not reached. Thresholds will
vary depending on the number of patients included in
a study, the statistical methods to determine cut-off
values [30], the underlying patient distribution [31],
and the assay used to quantify the metabolites.
Moreover, the threshold of a single metabolite in a
clinical study (in-vivo setting) may be influenced by
the relative concentrations of all the other metabolites
present in the same environment. Thus, they will
compete on the same binding site of the ER and con-
tribute to the numeric difference in cut-off values.
Intriguingly, all the above three cut-off values identify
a clinical relevant patient group with poor outcome in
the lower concentration extremities of Z-endoxifen and
Z-4OHtam. Admittedly, our supervised thresholds may
also have inflated the P values [32] and exaggerated the
survival differences between subgroups in the present
study. Hence, the threshold values in this learning set
must be interpreted with caution and validation of the
thresholds in a larger independent material is warranted
[33]. Importantly, consensus on the “correct clinical
threshold” should aim to characterize patients with low
benefit of tamoxifen with a certain safety margin to
avoid under-treatment.
Table 4 Overall survival; multivariable analysis including Z-4OHtam, Z-endoxifen, and AAS
Continuous variables Categorical variables
Factor HR per unit* 95% CI P Factor HR 95% CI P
Z-4OHtam Z-4OHtam > 3.26 nM 1
Adjusted† 0.81 0.66–0.99 0.040 ≤ 3.26 nM 4.86 1.88–12.54 0.001
Unadjusted 0.85 0.70–1.02 0.077 pT 1 1
2 2.59 1.11–6.05 0.028
pN Negative 1
Positive 2.89 1.12–7.49 0.029
Chemotherapy Yes 1
No 2.34 0.90– 6.11 0.083
Z-endoxifen Z–endoxifen > 9.00 nM 1
Adjusted† 0.99 0.96–1.02 0.365 ≤ 9.00 nM 5.65 2.00–16.00 0.001
Unadjusted 0.99 0.97–1.02 0.580 pT 1 1
2 2.44 1.08–5.49 0.032
pN Negative 1
Positive 2.40 0.99–5.80 0.052
Chemotherapy Yes 1
No 3.41 1.24–9.39 0.017
AAS AAS > 16.7 1
Adjusted† 0.99 0.97–1.01 0.313 ≤ 16.7 8.39 2.90–24.26 <0.001
Unadjusted 0.99 0.98–1.10 0.532 pT 1 1
2 2.60 1.15–5.91 0.022
pN Negative 1
Positive 3.40 1.26–9.15 0.016
Chemotherapy Yes 1
No 2.67 1.03–6.94 0.044
* Change in hazard ratio (HR) per 1 nM increase in serum concentration of Z-4OHtam, Z-endoxifen, change in HR per 1 unit Antiestrogenic Activity Score
(AAS; dimensionless)
† Adjusting variables: pT, pN, histological grade, estrogen receptor, progesterone receptor, age, and chemotherapy
CI confidence interval, pN pathologic node status, pT pathologic tumor size
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There are some limitations to the present study. First,
our patient population of 86 patients is small. Despite
the low number of patients, we were able to identify sig-
nificant associations between Z-4OH tam and Z-
endoxifen levels and outcome probably due to our long
follow-up time (median 13.8 years). The low number of
events in each subgroup calls for caution in interpreting
the results and may explain the lack of statistical power
to determine prognostic information from the CYP2D6
phenotype groups. Therefore, validation in larger study
cohorts is warranted. Furthermore, information on long-
term adherence (5 years) and co-medication, such as
CYP2D6 inhibitors, would have strengthened our study.
Entry of patients after a 3-year relapse-free period post-
surgery has created loss of early endpoints occurring
during the first 3 years of follow-up. This might have con-
tributed to the observed loss of prognostic information of
the proliferation-related variables such as pT, pN, and
histological grade in these luminal breast cancer subtypes.
This selection bias will favor patients with late events in
the natural course of their disease. In patients with
luminal breast cancers, approximately 75% of the breast
cancer-related deaths occur after 3 years [34]. As the
present study comprises only patients with this tumor
type with a long-term follow-up (i.e., up to 16.5 years) we
believe that our findings are of value for evaluating the 3-
year conditional survival in this patient group.
Conclusions
Although tamoxifen has been on the market for several
decades and is the most used drug against breast cancer,
its use may still be improved. The present study shows
that tamoxifen metabolism may predict breast cancer out-
come by measuring serum concentrations of active tam-
oxifen metabolites. Our results imply that patients with
serum Z-endoxifen levels lower than 9.00 nM or Z-
4OHtam levels lower than 3.26 nM have poorer long-
term BCSS and OS compared to patient with levels above
these thresholds. The results may translate into clinical
practice by means of therapeutic drug monitoring, which
represents a direct and applicable method to identify
breast cancer patients with poor tamoxifen metabolism
regardless of genotype and inhibiting drug interactions on
the CYP enzymes [35]. Dose adjustment or a switch to an
alternative endocrine treatment could avoid under-
treatment of such patients [36]. Our findings need to be
verified in larger studies, preferable in randomized trials
with a long follow-up time.
Additional files
Additional file 1: Table S1. Alleles analyzed by INFINITI®. (DOCX 14 kb)
Additional file 2: Table S2. Suppliers and catalog numbers for
tamoxifen metabolites. (DOCX 14 kb)
Additional file 3: Table S3. Imprecision and accuracy. (DOCX 16 kb)
Additional file 4: Table S4. Retention times, molecular weights, and
compound-dependent instrument settings. (DOCX 16 kb)
Additional file 5: Table S5. Linear dynamic range of the assay.
(DOCX 14 kb)
Additional file 6: Additional methods. Description of methods to
determine cut-off values. (DOCX 17 kb)
Additional file 7: Table S6. CYP2D6 allele frequencies. (DOCX 13 kb)
Additional file 8: Table S7. Concentrations of tamoxifen metabolites
stratified by metabolizer group. (DOCX 14 kb)
Additional file 9: Figure S1. Kaplan-Meier plot of breast cancer-
specific survival according to Antiestrogenic Activity Score.
(DOCX 109 kb)
Additional file 10: Table S8. Distribution of patients with high and
low Z-endoxifen (cut-off 9.0 nM) among patients with high and low
Z-4OHtam (cut-off 3.26 nM). (DOCX 13 kb)
Abbreviations
AAS: Antiestrogenic Activity Score; AI: Aromatase inhibitor; BC: Breast cancer;
BCSS: Breast cancer-specific survival; CI: Confidence interval;
CYP2D6: Cytochrome P450 2D6; EM: Extensive/normal metabolizer;
ER: Estrogen receptor; HR: Hazard ratio; HWE: Hardy-Weinberg equilibrium;
IM: Intermediate metabolizer; LC-MS/MS: Liquid chromatography-tandem
mass spectrometry; LLQ: Lower limits of quantification; OS: Overall survival;
PM: Poor metabolizer; PR: Progesterone receptor; UM: Ultra-rapid
metabolizer; vt: Variant type; wt: Wild-type; Z-4OHtam: Z-4-hydroxy-
tamoxifen; Z-endoxifen: Z-4-hydroxy-N-desmethyl-tamoxifen
Acknowledgements
The authors are grateful to the patients that participated in, and the researchers
that organized and conducted, the original study on which this retrospective
study is based.
Funding
The present study was funded by the Western Norway Regional Health
Authority. Highly appreciated financial support was received from the Folke
Hermannsen Foundation and the Inge Steenslands Foundation, Stavanger,
Norway.
Availability of data and materials
The data that support the findings of this study are available from OSBREAC
research group but restrictions apply to the availability of these data, which
were used under license for the current study, and so are not publicly
available. Data are, however, available from the authors upon reasonable
request and with permission of OSBREAC research group.
Authors' contributions
TH contributed to the laboratory analyses, statistical analyses, interpretation
of data, and drafted the manuscript. NH was responsible for the development
of the LC-MS/MS analyses along with EB and SH. BN contributed the clinical
samples from the OSBREAC group and was principal investigator of the OSLO1
study. EB performed the assessment of the pathological parameters and scorings.
VNK provided data from the OSBREAC group and DNA for the CYP2D6
genotyping. JTK gave expert advice on the statistical analyses. TLL gave
expert advice on several aspects of the study and interpretation of data.
GIGA performed purification of DNA from bone marrow and whole
blood samples. RHvS performed the CYP2D6 genotype analyses. EAMJ
and EAL contributed to the concept of the study and interpretation of
data. GM contributed to the concept of the study, the interpretation of
the data, and funding of the study. HS contributed to the concept of
the study, statistical analyses, interpretation of data, and funding of the
study. All co-authors contributed to the writing of the manuscript and
gave their final approval of the final version to be published.
Helland et al. Breast Cancer Research  (2017) 19:125 Page 11 of 13
Ethics approval and consent to participate
All participants have given written consent and the original OSLO1 study




The authors declare that they have no competing interests.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Hormone Laboratory, Haukeland University Hospital, Bergen, Norway.
2Department of Clinical Science, University of Bergen, Bergen, Norway. 3Core
Facility for Metabolomics, University of Bergen, Bergen, Norway. 4Department
of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo,
Norway. 5Institute of Clinical Medicine, Faculty of Medicine, University of
Oslo, Oslo, Norway. 6Pathology Department, Radium Hospital, Oslo University
Hospital, Oslo, Norway. 7Department of Cancer Genetics, Institute for Cancer
Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
8Department of Mathematics and Natural Science, University of Stavanger,
Stavanger, Norway. 9Department of Research, Stavanger University Hospital,
Stavanger, Norway. 10Department of Epidemiology, Rollins School of Public
Health, Winship Cancer Institute, Emory University, Atlanta, USA. 11Expert
Center Pharmacogenetics, Department of Clinical Chemistry, Erasmus
University Medical Center, Rotterdam, The Netherlands. 12Department of
Pathology, Stavanger University Hospital, Stavanger, Norway. 13Department
of Surgery, Section of Breast and Endocrine Surgery, Stavanger University
Hospital, Stavanger, Norway.
Received: 17 June 2017 Accepted: 8 November 2017
References
1. Early Breast Cancer Trialists' Collaborative Group. Effects of
chemotherapy and hormonal therapy for early breast cancer on
recurrence and 15-year survival: an overview of the randomised
trials. Lancet. 2005;365(9472):1687–717.
2. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux
A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, et al. Tamoxifen for the
prevention of breast cancer: current status of the National Surgical Adjuvant
Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 2005;97(22):1652–62.
3. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M,
Alencar VHM, Badran A, Bonfill X, et al. Long-term effects of continuing
adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of
oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Lancet. 2013;381(9869):805–816.
4. Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH,
Liedtke C, Marschner N, Mobus V, Scheithauer H, et al. 14th St. Gallen
International Breast Cancer Conference 2015: evidence, controversies,
consensus—primary therapy of early breast cancer: opinions expressed by
German experts. Breast Care (Basel, Switzerland). 2015;10(3):211–9.
5. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M,
Thürlimann B, Senn H-J, Panel Members. Personalizing the treatment of
women with early breast cancer: highlights of the St Gallen International
Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann
Oncol. 2013;24(9):2206–23.
6. Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. PharmGKB
summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics.
2013;23(11):643–7.
7. Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, Nüssler A,
Neuhaus P, Zanger UM, Eichelbaum M. The influence of CYP2B6, CYP2C9
and CYP2D6 genotypes on the formation of the potent antioestrogen Z‐4‐
hydroxy‐tamoxifen in human liver. Br J Clin Pharmacol. 2002;54(2):157–67.
8. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren
G, Steen VM, Lien EA. Effects of CYP2D6 and SULT1A1 genotypes including
SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol. 2007;
19(1):56–61.
9. Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H. Pharmacogenomics of
tamoxifen: roles of drug metabolizing enzymes and transporters. Drug
Metab Pharmacokinet. 2012;27(1):122–31.
10. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds
C, Couch FJ, Lingle WL, Flockhart DA, et al. Pharmacogenetics of tamoxifen
biotransformation is associated with clinical outcomes of efficacy and hot
flashes. J Clin Oncol. 2005;23(36):9312–8.
11. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R,
Dell’Orto P, Biasi MO, Thürlimann B, Lyng MB, et al. CYP2D6 genotype and
tamoxifen response in postmenopausal women with endocrine-responsive
breast cancer: the Breast International Group 1-98 Trial. J Natl Cancer Inst.
2012;104:441–51.
12. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S.
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen
response in postmenopausal patients with breast cancer. Breast Cancer Res.
2007;9(1):R7.
13. Hertz DL, McLeod HL, Irvin WJ. Tamoxifen and CYP2D6: a contradiction of
data. Oncologist. 2012;17(5):620–30.
14. Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen
therapy: time to pause for reflection? Lancet Oncol. 2009;10(8):825–33.
15. Jager NGL, Rosing H, Linn SC, Schellens JHM, Beijnen JH. Importance of
highly selective LC–MS/MS analysis for the accurate quantification of
tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.
Breast Cancer Res Treat. 2012;133(2):793–8.
16. Barginear M, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick
R. Increasing tamoxifen dose in breast cancer patients based on CYP2D6
genotypes and endoxifen levels: effect on active metabolite isomers and
the antiestrogenic activity score. Clin Pharmacol Ther. 2011;90(4):605.
17. Wiedswang G, Borgen E, Kåresen R, Kvalheim G, Nesland JM, Qvist H,
Schlichting E, Sauer T, Janbu J, Harbitz T, et al. Detection of isolated tumor
cells in bone marrow is an independent prognostic factor in breast cancer.
J Clin Oncol. 2003;21(18):3469–78.
18. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol.
2008;167(4):492–9.
19. Lash TL, Cole SR. Immortal person-time in studies of cancer outcomes. J
Clin Oncol. 2009;27(23):e55–6.
20. Ho AMH, Dion PW, Ng CSH, Karmakar MK. Understanding immortal time
bias in observational cohort studies. Anaesthesia. 2013;68(2):126–30.
21. Jaremko M, Kasai Y, Barginear MF, Raptis G, Desnick RJ, Yu C. Tamoxifen
metabolite isomer separation and quantification by liquid chromatography-
tandem mass spectrometry. Anal Chem. 2010;82(24):10186–93.
22. Lien EA, Søiland H, Lundgren S, Aas T, Steen VM, Mellgren G, Gjerde J.
Serum concentrations of tamoxifen and its metabolites increase with age
during steady-state treatment. Breast Cancer Res Treat. 2013;141(2):243–8.
23. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM,
Hillman G, Fontecha MR, Lawrence HJ, et al. Tamoxifen metabolite
concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin
Pharmacol Ther. 2011;89(5):718–25.
24. Saladores P, Murdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev
B, Eccles B, Gerty S, Tfayli A, et al. Tamoxifen metabolism predicts drug
concentrations and outcome in premenopausal patients with early breast
cancer. Pharmacogenomics J. 2015;15(1):84–94.
25. Johansson H, Gandini S, Serrano D, Gjerde J, Lattanzi M, Macis D, Guerrieri-
Gonzaga A, Aristarco V, Mellgren G, Lien E, et al. A pooled analysis of
CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
Breast Cancer Res Treat. 2016;159(1):97–108.
26. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon
W, Eichelbaum M, Brauch H. Breast cancer treatment outcome with
adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J
Clin Oncol. 2007;25(33):5187–93.
27. Lintermans A, Van Asten K, Jongen L, Blomme C, Lambrechts D, Van Calster
B, Poppe A, Wildiers H, Dieudonné A-S, Decloedt J. Prospective study
evaluating the effect of impaired tamoxifen metabolisation on efficacy in
breast cancer patients receiving tamoxifen in the neo-adjuvant or
metastatic setting. J Clin Oncol. 2016;34(15_suppl):523.
28. Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M,
Buhrow SA, Safgren SL, McGovern RM, et al. First-in-human phase I study of
the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory
metastatic breast cancer. J Clin Oncol. 2017;35:3391–400.
29. de Vries Schultink AHM, Alexi X, van Werkhoven E, Madlensky L, Natarajan L,
Flatt SW, Zwart W, Linn SC, Parker BA, Wu AHB, et al. An Antiestrogenic
Helland et al. Breast Cancer Research  (2017) 19:125 Page 12 of 13
Activity Score for tamoxifen and its metabolites is associated with breast
cancer outcome. Breast Cancer Res Treat. 2017;161(3):567–74.
30. Mazumdar M, Glassman JR. Categorizing a prognostic variable: review of
methods, code for easy implementation and applications to decision‐
making about cancer treatments. Stat Med. 2000;19(1):113–32.
31. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using
“optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer
Inst. 1994;86(11):829–35.
32. Lakens D. On the challenges of drawing conclusions from p-values just
below 0.05. Peer J. 2015;3:e1142.
33. Baak JPA. The framework of pathology: good laboratory practice by
quantitative and molecular methods. J Pathol. 2002;198(3):277–83.
34. Engstrøm MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA,
Vatten LJ, Bofin AM. Molecular subtypes, histopathological grade and
survival in a historic cohort of breast cancer patients. Breast Cancer Res
Treat. 2013;140(3):463–73.
35. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC,
Paszat LF. Selective serotonin reuptake inhibitors and breast cancer
mortality in women receiving tamoxifen: a population based cohort study.
BMJ. 2010;340:c693.
36. Jager NG, Linn SC, Schellens JH, Beijnen JH. Tailored tamoxifen treatment for
breast cancer patients: a perspective. Clin Breast Cancer. 2015;15(4):241–4.




unikasjonsavdelingen, UiB  /  Trykk: Skipnes Kom
m
unikasjon AS
uib.no
ISBN: 978-82-308-3557-9
